Poster Presentations Session I

HEALTH CARE USE AND POLICY STUDIES Adherence/Compliance

PHP1	EFFECT OF PRESCRIPTION COPAY ON MEDICATION UTILIZATION
	Gause D, Doyle JJ, Plauschinat C
	Novartis Pharmaceuticals, East Hanover, NJ, USA

PHP2	ADHERENCE TO EVIDENCE-BASED GUIDELINES AND MEDICATION COMPLIANCE FOR MULTIPLE CHRONIC DISEASES IN A MANAGED CARE DATABASE
	Burch SP, Priest JL, Cook CL, Cantrell CR
	GlaxoSmithKline, Research Triangle Park, NC, USA

PHP3	IS THERE AN ACCEPTABLE LEVEL OF MEDICATION ADHERENCE? A REVIEW OF RETROSPECTIVE ADHERENCE EVALUATION STUDIES
	Visaria J, Seoane-Vazquez E, Schwartzbaum J, Szeinbach SL
	The Ohio State University, Columbus, OH, USA

PHP4	THE IMPACT OF COPAYMENTS OR BRAND NAMED DRUG ON MEDICATION PERSISTENCE
	Wu J¹, Nichol MB1, Knight TK1, Mahoney J², Berman C²
	1University of Southern California, Los Angeles, CA, USA, 2Pitney Bowes Inc, Stamford, CT, USA

PHP5	ADHERENCE AND SWITCHING WITH DRUGS USED FOR THE PROPHYLAXIS OF ORGAN REJECTION
	Varasteh LT, Pedan A, Asumeng-Denteh E
	Adheris, Inc, Burlington, MA, USA

PHP6	PREDICTORS OF NONCOMPLIANT COST-CUTTING BEHAVIORS AMONG ADULTS IN THE UNITED STATES
	Kannan H, Bolge SC
	Consumer Health Sciences, Princeton, NJ, USA

PHP7	THE EFFECTS OF NONCOMPLIANT COST-CUTTING BEHAVIORS ON OUTCOMES AMONG ADULTS IN THE UNITED STATES
	Bolge SC, Kannan H
	Consumer Health Sciences, Princeton, NJ, USA

PHP8	THE EFFECTS OF NONCOMPLIANT COST-CUTTING BEHAVIORS ON INDIRECT COSTS AMONG ADULTS IN EUROPE
	Bolge SC, Kannan H
	Consumer Health Sciences, Princeton, NJ, USA

PHP9	UNITED STATES PHYSICIANS AND IN-OFFICE DRUG ADMINISTRATION: THE CONCEPT OF “INCIDENT-TO” SERVICES
	Pierce CA¹, Baker JJ²
	1UCB Celltech, Slough, UK, 2UCB, Slough, UK

HEALTH CARE USE & POLICY STUDIES Consumer Role in Health Care

PHP10	CREATION OF A RISK RATING SYSTEM TO COMMUNICATE DRUG SAFETY INFORMATION TO CONSUMERS
	Cascade EF¹, Stephenson H²
	1Quintiles, Inc, Falls Church, VA, USA, ²iGuard, Inc, Princeton, NJ, USA

PHP11	ETHNIC DISPARITIES IN HOSPITAL DISCHARGES AGAINST MEDICAL ADVICE AMONG CARDIOVASCULAR DISEASE PATIENTS: THE ROLE OF HOSPITAL QUALITY
	Onukwugha E¹, Weir MR², Saunders E³, Shaya FT⁴
	1University of Maryland School of Pharmacy, Baltimore, Baltimore, MD, USA, 2University of Maryland, Baltimore, MD, USA, 3University of Maryland, Medical System, Baltimore, MD, USA, 4University of Maryland School of Pharmacy, Baltimore, MD, USA

PHP12	ASSOCIATION BETWEEN DIRECT-TO-CONSUMER ADVERTISING (DTCA) AND DRUG UTILIZATION IN THE U.S. MEDICAID MARKET FOR SELECTED DRUG CLASSES
	Sheridan J¹, Guo JJ², Kelton CM², Shelly D³
	1Medpace Reference Laboratories, Cincinnati, OH, USA, 2University of Cincinnati, Cincinnati, OH, USA, 3Meridian Life Science, Inc, Cincinnati, OH, USA

HEALTH CARE USE & POLICY STUDIES Drug or Devices & Health Policy

PHP13	CONTROLLED SUBSTANCE WASTE IN HOME HOSPICE SETTINGS
	Maxwell T¹, Woods CJ1, Steward K¹, Knowlton M¹, Liao D²
	1excelleRx, Inc, Philadelphia, PA, USA, 2Jefferson Medical College, Philadelphia, PA, USA

PHP14	ESTIMATION OF USAGE OF NEW DRUG AFTER REIMBURSEMENT FOR BUDGET IMPACT ANALYSIS
	Park SE, Lee SM, Yim EY, Choi HW, Choi DH, Lim SH, Yi SY, Choi MR
	Health Insurance Review & Assessment Services, Seoul, South Korea

PHP15	EVALUATING THE USE OF PROVISIONAL PATENTS BY THE PHARMACEUTICAL INDUSTRY: THE EXPERIENCE OF THE UNITED STATES
	Beyer AP, Visaria J, Seoane-Vazquez E, Szeinbach SL
	The Ohio State University, Columbus, OH, USA

PHP16	IMPROVING HEALTH TECHNOLOGY APPRAISAL AND DECISION-MAKING: WHAT HAS THE BRITISH PARLIAMENT'S INQUIRY OF NICE TAUGHT US?
	Cross JT, Garrison LP, Sullivan SD
	1Pharmatelligence Limited, Cardiff, UK, ²Eli Lilly and Company Limited, Surrey, UK, 3Cardiff University, Cardiff, UK

PHP17	HOW MANDATORY PRICE REDUCTION OF REIMBURSED PHARMACEUTICALS COULD RESULT IN INCREASED PHARMACEUTICAL EXPENDITURE?
	Bacskai M¹, Komaromi T¹, Nagy B¹, Kalo Z²
	1Healthware Consulting Ltd, Budapest, Hungary, ²Eotvos Lorand University, Budapest, Hungary

PHP18	WITHDRAWN

PHP19	EFFECT OF PRESCRIPTION DRUG COVERAGE ON HEALTH AMONG CHRONICALLY ILL ELDERLY POPULATION
	Khan N¹, Kaestner R²
	1University of New Mexico, Albuquerque, NM, USA, 2University of Illinois at Chicago, Chicago, IL, USA

PHP20	PREDICTORS OF ENROLLMENT IN MEDICARE PART D: THE EXPERIENCE OF MEDICARE DRUG DEMONSTRATION PARTICIPANTS WITH RHEUMATOID ARTHRITIS AND MULTIPLE SCLEROSIS
	Polinski JM¹, Mohr PE², Johnson L²
	1Brigham and Women's Hospital, Boston, MA, USA, ²Centers for Medicare and Medicaid Services, Baltimore, MD, USA

PHP21	CLINICALLY SIGNIFICANT DRUG-DRUG INTERACTION PROFILES IN THE ELDERLY – A CALIFORNIA QUALITY IMPROVEMENT ORGANIZATION (QIO) COLLABORATIVE EXPERIENCE
	Kwok P, Nuñez S, Sabogal F
	Lumetra, San Francisco, CA, USA

PHP22	MEDICARE SPENDING GROWTH FOR DIAGNOSTIC IMAGING AND ACCESS TO CARE
	Lee DW
	GE Healthcare, Waukesha, WI, USA

PHP23	SPECIALTY BIOLOGIC DRUG COVERAGE UNDER MEDICARE PART D: THE EXPERIENCE OF VULNERABLE BENEFICIARIES WITH RHEUMATOID ARTHRITIS (RA) AND MULTIPLE SCLEROSIS (MS)
	Polinski JM¹, Mohr PE², Johnson L²
	1Brigham and Women's Hospital, Boston, MA, USA, ²Centers for Medicare and Medicaid Services, Baltimore, MD, USA

PHP24	THE IMPACT OF BENEFIT PLAN DESIGN ON COST AND HEALTH OUTCOMES
	Chin W¹, Bonnett C², Jorch U³
	1Ilex Consulting, Toronto, ON, Canada, ²H3 Consulting, Toronto, ON, Canada, 3Jorch Consulting, Toronto, ON, Canada

PHP25	TOWARD HIGH PERFORMANCE 'PHARMACARE' SYSTEMS: A REVIEW OF EXPERIENCES IN SEVEN COUNTRIES
	Morgan S¹, Kennedy J², Roughead L³, Boothe K¹, McMahon M⁴, Watson D⁵
	1University of British Columbia, Vancouver, BC, Canada, 2Washington State University, Spokane, WA, USA, 3University of South Australia, Adelaide, South Australia, Australia, 4Institute for Health Services and Policy Research, Toronto, ON, Canada, 5Health Council of Canada, Vancouver, BC, Canada

PHP26	RESEARCH AND MARKETING COMPLEMENTARITY IN PHARMACEUTICAL FIRMS: EMPIRICAL EVIDENCE
	Snyder S
	Lehigh University, Bethlehem, PA, USA

PHP27	ESTIMATION AND COMPARISON OF ORTHOTIC BRACE COSTS WITH REIMBURSEMENT TARIFFS AND RETAIL PRICES IN BELGIUM
	Simoens S¹, Debruyne H², Moldenaers I², Guillaume P², De Coster S¹, Van den Steen D³, Van de Sande S³, Ramaekers D³, Lona M³
	1Katholieke Universiteit Leuven, Leuven, Belgium, ²Deloitte Consulting, Diegem, Belgium, 3Belgian Healthcare Knowledge Centre, Brussels, Belgium

PHP28	THE PROCESS OF UPDATING THE NATIONAL LIST OF HEALTH SERVICES IN ISRAEL: IS IT LEGITIMATE? IS IT FAIR?
	Greenberg D¹, Siebzehner MI², Pliskin JS¹
	1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2The Israeli Center for Technology Assessment in Health Care, Tel Hashomer, Israel

PHP29	STAKEHOLDER PERSPECTIVES ON ECONOMIC EVALUATION: THE CASE OF NICE
	Sorenson C¹, Drummond MF²
	1London School of Economics, London, UK, 2University of York, York, Heslington, UK

HEALTH CARE USE & POLICY STUDIES Disease Management

PHP30	COST-EFFECTIVENESS ANALYSIS AND RETURN ON INVESTMENT OF HIGH COST PATIENTS MANAGEMENT PROGRAM WITHIN A PRIVATE HEALTH CARE PLAN IN BRAZIL
	Abicalaffe CL, Justus J
	Impacto Tecnologias Gerenciais em Saude, Curitiba, Parana, Brazil

PHP31	DRUG PROXIES FOR IDENTIFYING SPECIFIC DIAGNOSES IN MEDICARE PART D
	Livengood KB, Harada A, Gong S, Stockl K, Le L, Zhang S
	Prescription Solutions, United Health Group, Irvine, CA, USA

HEALTH CARE USE & POLICY STUDIES Drug Use

PHP32	WHAT'S DRIVING PRESCRIPTION COPAYMENTS?
	Cox E¹, Svirnovskiy Y²
	1Express Scripts Inc, Saint Louis, MO, USA, ²Express Scripts, Saint Louis, MO, USA

PHP33	HERB/DIETARY SUPPLEMENT AND PRESCRIPTION DRUG USE TRENDS AMONG US ADULTS, 1999-2004
	Lin HW¹, Pickard AS², Wittenberg RD¹, Tsai HH³, Lin SJ¹, Shaw JW¹
	1University of Illinois at Chicago, Chicago, IL, USA, ²College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 3China Medical University, Taichung, Taiwan, Changhua City, Changhua County, Taiwan

PHP34	PRINCIPAL COMPONENTS ANALYSIS OF DRUG UTILIZATION AND EXPENDITURE TRENDS FOR MAJOR THERAPEUTIC CLASSES IN U.S. MEDICAID PROGRAMS
	Jing Y¹, Nguyen K¹, Guo JJ¹, Fan H², Li X¹, Kelton CM¹
	1University of Cincinnati, Cincinnati, OH, USA, ²Covance Inc, Sun Prairie, WI, USA

PHP35	CHARACTERIZING PHARMACY AND MEDICAL CLAIMS FOR A PRIVATE INSURANCE POLYPHARMACY POPULATION
	Bresnahan BW¹, Koprowicz K1, Choudhury SR², Garrison L1, Wong E²
	1University of Washington, Seattle, WA, USA, 2Premera Blue Cross, Mountlake Terrace, WA, USA

PHP36	RELATIONSHIP OF DOCTOR SHOPPING AND POLYPHARMACY: A NATIONWIDE STUDY IN TAIWAN
	Chou LF¹, Chen TJ²
	1National Chengchi University, Taipei, Taiwan, 2Taipei Veterans General Hospital, Taipei, Taiwan

PHP37	THE EPIDEMIOLOGY AND OUTCOMES OF PATIENTS BY SERUM DIGOXIN LEVELS DURING HOSPITALIZATION
	Gupta V, Derby KG, Goetz A, Johannes RS, Darin R
	Cardinal Health, Marlborough, MA, USA

PHP38	A QUALITATIVE REVIEW OF OFF-LABEL USES OF INTRAVENOUS IMMUNGLOBULIN
	Leong H¹, Stachnik JM², Bonk ME¹, Matuszewski K¹
	¹University HealthSystem Consortium, Oak Brook, IL, USA, 2University of Illinois Medical Center, Chicago, IL, USA

PHP39	THE EPIDEMIOLOGY AND OUTCOMES OF PATIENTS TREATED WITH HEPARIN DURING HOSPITALIZATION
	Gupta V, Hart J, Frisch I, Hyde LA, Goetz A, Johannes RS, Darin R
	Cardinal Health, Marlborough, MA, USA

HEALTH CARE USE & POLICY STUDIES Equity and Access

PHP40	ANALYZING INEQUITY IN HEALTH CARE UTILIZATION BY THE US POPULATION
	Kawatkar AA, Nichol MB
	University of Southern California, Los Angeles, CA, USA

PHP41	PATIENT RACE AND MEDICATION CHOICE FOR HYPERCHOLESTEROLEMIA, HYPERTENSION, AND DIABETES
	Rathore SS¹, Alexander GC², Ketcham JD³, Epstein AJ¹
	¹Yale University, New Haven, CT, USA, 2University of Chicago, Chicago, IL, USA, 3Arizona State University, Tempe, AZ, USA

PHP42	PHYSICIANS' VIEWS REGARDING PRESCRIPTION DRUG ACCESS UNDER MEDICARE PART D
	Epstein AJ¹, Rathore SS¹, Alexander GC², Ketcham JD³
	¹Yale University, New Haven, CT, USA, 2University of Chicago, Chicago, IL, USA, 3Arizona State University, Tempe, AZ, USA

PHP43	PHYSICIANS' VIEWS REGARDING THE IMPACT OF MEDICARE PART D DRUG COVERAGE FOR DUAL-ELIGIBLE PATIENTS
	Epstein AJ¹, Rathore SS¹, Alexander GC², Ketcham JD³
	¹Yale University, New Haven, CT, USA, 2University of Chicago, Chicago, IL, USA, 3Arizona State University, Tempe, AZ, USA

HEALTH CARE USE & POLICY STUDIESFormulary Development

PHP44	SOURCES OF MEDICAL INFORMATION AND DEGREE OF TRUST PLACED IN THEM BY RUSSIAN DOCTORS
	Zaytsev A
	State Institute for Advanced Training of Physicians, Ministry of Defense, Moscow, Russia

PHP45	COMMON DRUG REVIEW (CDR) RECOMMENDATIONS: DOES COST-EFFECTIVENESS MATTER?
	Rocchi A, Miller B
	Axia Research, Hamilton, ON, Canada

HEALTH CARE USE & POLICY STUDIESHealth Care Expenditure / Information / Management / Reimbursement

PHP46	IMPACT OF A DRUG POLICY ON AVAILABILITY AND DRUG COST CONTAINMENT IN A TERTIARY CARE HOSPITAL: 10 YEARS OF EXPERIENCE
	Sharma S¹, Agarwal AK¹, Gupta M¹, Roy Choudhury R²
	¹Institute of Human Behaviour & Allied Sciences, Delhi, India, ²Delhi Society for Promotion of Rational Drug Use, Delhi, India

PHP47	ASSESSMENT OF NATIONAL MEDICARE PART D ESTIMATED ANNUAL COSTS FOR 2007 AND 2008 USING A PATIENT COHORT
	Walberg MP, Patel RA, Amaral M
	University of the Pacific, Stockton, CA, USA

PHP48	THE STATE OF HEALTH ECONOMICS AND PHARMACOECONOMICS EVALUATION RESEARCH IN ZIMBABWE
	Gavaza P¹, Rascati KL², Lawson KA¹, Brown CM¹, Mann T¹
	¹University of Texas at Austin, Austin, TX, USA, 2The University of Texas at Austin, Austin, TX, USA

PHP49	FRAMEWORK AND METHODOLOGY TO IDENTIFY AND ASSESS PHARMACIST-SENSITIVE OUTCOMES IN COLLABORATIVE MEDICATION MANAGEMENT
	Bajcar J, Machado M, Einarson TR
	University of Toronto, Toronto, ON, Canada

PHP50	A TYPOLOGY OF AFRICAN AMERICAN COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE AND ITS CORRELATES FROM THE ANDERSEN HEALTH CARE UTILIZATION MODEL
	Bohman TM, Barner JC, Richards KM, Brown C
	University of Texas at Austin, Austin, TX, USA

PHP51	COMPARISONS OF RELATIVE RISKS OF SERIOUS COMORBIDITIES AMONG EMPLOYEES WITH AND WITHOUT INSOMNIA, GERD, HEPATITIS C, MULTIPLE SCLEROSIS, AND CHRONIC CONSTIPATION
	Brook RA¹, Kleinman NL,², Melkonian AK³, Smeeding J⁴
	¹The JeSTARx Group, Newfoundland, NJ, USA, ²HCMS Group, Paso Robles, CA, USA, 3The HCMS Group, Cheyenne, WY, USA, 4The JeSTARx Group, Dallas, TX, USA

PHP52	CHANGES IN PHARMACIST-PROVIDED MEDICATION THERAPY MANAGEMENT SERVICES: ANALYSIS OF ONE INNOVATIVE COMPANY'S MTM SERVICE CLAIMS OVER TIME
	Barnett MJ¹, Frank J², Wehring HJ¹, Kumbera P², Newland B², Perry PJ¹
	¹Touro University- California College of Pharmacy, Vallejo, CA, USA, 2Outcomes Pharmaceutical Health Care, Des Moines, IA, USA

PHP53	TRENDS IN COMMUNITY BASED ADVERSE DRUG EVENTS IN THE UNITED STATES: 1996–2005
	Bhanegaonkar AJ, Moffett ML
	West Virginia University, Morgantown, WV, USA

PHP54	PREVALENCE OF CONDITIONS IN THE US EMPLOYER-INSURED POPULATION
	Hansen LG¹, Chang S², Foley K³
	¹Thomson Healthcare, Northwood, NH, USA, 2Thomson Healthcare, Washington, DC, USA, 3Thomson Healthcare, Philadelphia, PA, USA

PHP55	DEVELOPING A PRACTICE –BASED RESEARCH NETWORK (PBRN) TO EVALUATE MULTI-CENTER PHARMACIST-CONDUCTED MEDICATION THERAPY MANAGEMENT PROGRAMS (MTMPS) USING THE ECHO MODEL
	Coletto M, Pinto SL
	University of Toledo, Toledo, OH, USA

PHP56	COMPARATIVE ANALYSIS OF THE ACCESS TO PHARMACEUTICALS IN SELECTED EAST EUROPEAN COUNTRIES
	Lakic D¹, Tasic L², Petrova GI³
	¹Belgrade University, Faculty of Pharmacy, Belgrade, Serbia and Montenegro, 2University of Belgrade, Belgrade, Serbia and Montenegro, 3Medical University, Faculty of Pharmacy, Sofia, Bulgaria

PHP57	FACTOR ANALYSIS OF PHARMACISTS' PERCEIVED BARRIERS TO PROVISION OF MEDICATION THERAPY MANAGEMENT SERVICES (MTMS) IN WEST VIRGINIA
	Blake KB, Madhavan SS, Moffett ML, Scott V, Elswick BM
	West Virginia University, Morgantown, WV, USA

PHP58	ECONOMIC-BASED OUTCOMES ASSESSMENT OF PHARMACEUTICAL CARE IN A UNIVERSITY HOSPITAL MEDICAL INTENSIVE CARE UNIT IN TAIWAN
	Huang CY¹, Hao HS², Hsieh YW¹, Tsai HY²
	¹China Medical University Hospital, Taichung, Taiwan, ²China Medical University, Taichung, Taiwan

PHP59	DRUG THERAPY PROBLEMS: DOES PHARMACIST'S INTERVENTION SAVE COST?
	Udezi WA¹, Usifoh CO¹, Amibor KC²
	¹University of Benin, Benin, Edo, Nigeria, ²Federal Medical Centre, Asaba, Delta, Nigeria

PHP60	DEVELOPMENT OF A DRUG INVENTORY MANAGEMENT MODEL FOR THE STATE HOUSE MEDICAL CENTRE, ABUJA, NIGERIA
	Eti-ukwu A¹, Peters A²
	¹State House Medical Centre, Abuja, FCT, Nigeria, ²University of Lagos, Lagos, Nigeria

PHP61	PAY-FOR-PERFORMANCE PROGRAMME FOR BRAZILIAN PRIVATE HEALTH PLAN: HOW TO IMPLEMENT AND MEASURE
	Abicalaffe CL
	Impacto Tecnologias Gerenciais em Saude, Curitiba, Parana, Brazil

PHP62	HOW EVIDENCE-BASED AND TIMELY ARE MEDICARE COVERAGE DECISIONS FOR NEW TECHNOLOGIES: AN EMPIRICAL ANALYSIS, 1999-2007
	Kamae M, Palmer JA, Neumann PJ
	Tufts-New England Medical Center, Boston, MA, USA

PHP63	SEGMENTED REGRESSION ANALYSIS OF INTERRUPTED TIME SERIES PRESCRIPTION GROSS MARGIN TRENDS FOR INDEPENDENT PHARMACIES BEFORE AND AFTER MEDICARE PART D
	Richards KM, Shepherd MD
	University of Texas, Austin, TX, USA

PHP64	THE EFFECT OF THE PERFORMANCE VOLUME LIMIT (PVL) ON THE DRG FINANCING OF THE HUNGARIAN HOSPITALS
	Boncz I¹, Sebestyén A², Betlehem J¹, Brodszky V3, Karpati K3, Ágoston I¹, Kriszbacher I¹, Gulacsi L3
	¹University of Pécs, Pécs, Hungary, ²National Health Insurance Fund Administration, Budapest, Hungary, 3Corvinus University of Budapest, Budapest, Hungary

PHP65	THE ROLE OF THE ACADEMY OF MANAGED CARE PHARMACY (AMCP) FORMAT IN MANAGED CARE FORMULARY AND COVERAGE DECISIONMAKING
	Schaefer C¹, Lerner J², Santillo C², Goss T²
	¹Covance Market Access, Gaithersburg, MD, USA, ²Covance Market Access Services, Gaithersburg, MD, USA

PHP66	EVALUATION OF INDIRECT COMPARISONS USED FOR REIMBURSEMENT DECISIONS: LESSONS FROM THE COMMON DRUG REVIEW
	Vicente C¹, Piwko C¹, Chou R¹, Maturi B²
	¹PIVINA Consulting Inc, Thornhill, ON, Canada, ²Wyeth Pharmaceuticals, Markham, ON, Canada

PHP67	THRESHOLD VALUE FOR A QALY - CORRELATION WITH DISEASE SEVERITY AND DECISION UNCERTAINTY
	Hugosson K¹, Engstrom A²
	¹Pharmaceutical Benefits Board, Solna, Sweden, ²LFN Pharmaceutical Benefits Board, Solna, Sweden

PHP68	CHARACTERISTICS OF RISK-SHARING SCHEMES IN EUROPE
	Muston D¹, Perard R¹, Nixon F²
	¹Heron Evidence Development Ltd, Letchworth Garden City, Hertfordshire, UK, ²Heron Evidence Development Ltd, Letchworth Garden City, UK

HEALTH CARE USE & POLICY STUDIESPrescribing Behavior

PHP69	THE PRESCRIBING OF CHINESE HERBAL PRODUCTS IN TAIWAN: A CROSS-SECTIONAL ANALYSIS OF THE NATIONAL HEALTH INSURANCE REIMBURSEMENT DATABASE
	Hsieh SC1, Wang JD2, Lee CF3
	1Center for Drug Evaluation, Taipei City, Taiwan, 2National Taiwan University, College of Public Health, Taipei, Taiwan, 3Tri-Service General Hospital, Taipei, Taiwan

PHP70	PHYSICIANS' KNOWLEDGE OF LABELED DRUG INDICATIONS AND ATTITUDES REGARDING OFF-LABEL USE: RESULTS OF A NATIONAL SURVEY OF GENERAL INTERNISTS AND PSYCHIATRISTS
	Alexander GC¹, Chen D², Moloney R¹, Wynia MK3
	¹University of Chicago, Chicago, IL, USA, ²University of Virginia, Charlottesville, VA, USA, 3American Medical Association, Chicago, IL, USA

HEALTH CARE USE & POLICY STUDIES Patient/Provider/Payer/Researcher Education

PHP71	PHARMACY STUDENTS' ABILITY TO RECOGNIZE DRUG-DRUG INTERACTIONS (DDIS)
	Saverno K, Malone DC
	University of Arizona College of Pharmacy, Tucson, AZ, USA

HEALTH CARE USE & POLICY STUDIESPharmacogenomics

PHP72	GENETIC TESTING FOR WARFARIN INITIATION: A COST-EFFECTIVENESS ANALYSIS BASED ON CURRENT EVIDENCE
	Meckley LM¹, Gudgeon JM², Anderson JL², Williams MS², Veenstra DL¹
	¹University of Washington, Seattle, WA, USA, ²Intermountain Healthcare, Salt Lake City, UT, USA

PHP73	CONSUMPTION PATTERNS AND ECONOMIC BURDEN OF DRUGS IN FORTALEZA, BRAZIL
	Barroso M¹, Chaves E¹, Machado M², Coelho HLL¹
	¹Universidade Federal do Ceara, Fortaleza, Ceara, Brazil, ²University of Toronto, Toronto, ON, Canada

PHP74	THE CADTH GUIDELINES FOR THE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES: DO CURRENT CANADIAN ECONOMIC EVALUATIONS PASS THE TEST?
	Lim ME, Bowen J, McCarron CE, Blackhouse G, Hopkins R, O'Reilly D, Goeree RA, Tarride JE
	McMaster University, Hamilton, ON, Canada

HEALTH CARE USE & POLICY STUDIESPost Marketing Studies

PHP75	SATISFACTION WITH MEDICATION: PRELIMINARY RESULTS FROM A NOVEL PATIENT REGISTRY TRACKING SATISFACTION WITH DIFFERENT CHRONIC MEDICATIONS
	Bharmal M¹, Cascade EF², Gemmen EK3
	¹Quintiles, Falls Church, VA, USA, ²Quintiles, Inc, Falls Church, VA, USA, 3Quintiles Strategic Research & Safety, Falls Church, VA, USA

HEALTH CARE USE & POLICY STUDIES Quality of Care

PHP76	ALBERTA'S HEALTH SYSTEM PERFORMANCE: A BALANCED SCORECARD STUDY
	Thanh NX, Jonsson E
	Institute of Health Economics, Edmonton, AB, Canada

PHP77	EVALUATION OF THE IMPACT OF PATIENT SAFETY ACTIVITIES ON THE NUMBER OF VOLUNTARY INCIDENT REPORTS AT TEACHING HOSPITALS IN JAPAN
	Fukuda H, Imanaka Y, Hirose M, Hayashida K
	Kyoto University, Kyoto, Japan

PHP78	STABILITY OF PHYSICIAN PERFORMANCE ON PAY-FOR-PERFORMANCE PROCESS MEASURES OVER TIME: EFFECT OF PATIENT DENOMINATOR THRESHOLDS
	Marehbian J¹, Kang N¹, Taira Juarez D², Chung R², Chen JY3, Legorreta AP4
	¹Health Benchmarks, Inc, Woodland Hills, CA, USA, ²HMSA, Honolulu, HI, USA, 3Health Benchmarks Inc, Woodland Hills, CA, USA, 4UCLA School of Public Health, Los Angeles, CA, USA

PHP79	PHYSICIAN QUALITY MEASUREMENT IN THE HEALTH PLAN PPO SETTING: THE IMPORTANCE OF SCORING ALGORITHMS
	Kang N¹, Taira Juarez D², Chung R², Chen JY3, Legorreta AP4
	¹Health Benchmarks, Inc, Woodland Hills, CA, USA, ²HMSA, Honolulu, HI, USA, 3Health Benchmarks Inc, Woodland Hills, CA, USA, 4UCLA School of Public Health, Los Angeles, CA, USA

HEALTH CARE USE & POLICY STUDIES Regulation of Health Care Sector

PHP80	ANALYSIS OF FDA WARNING LETTERS AND NOTICES TO MANUFACTURERS OF PHARMACEUTICALS CONCERNING HEALTH OUTCOMES-RELATED PROMOTIONAL CLAIMS VIOLATIONS
	Kamal KM¹, Rane PB¹, Parekh RH1, Desselle SP², Zacker C3
	¹Duquesne University, Pittsburgh, PA, USA, ²University of Oklahoma-Tulsa, Tulsa, OK, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PHP81	PROGRESSIVE LICENSING AND VALUE FOR MONEY: USE OF RESPONDER ANALYSIS IN ECONOMIC EVALUATION
	McDonald HP¹, Rebeira M¹, Isogai P², Mittmann N², Jaszewski B¹
	¹Bayer Healthcare, Toronto, ON, Canada, ²HOPE Research Centre, Toronto, ON, Canada

PHP82	RECENT TRENDS IN THE INCLUSION OF PATIENT-REPORTED OUTCOME (PRO) DATA IN APPROVED DRUGS LABELING BY FDA AND EMEA
	Caron M¹, Emery MP¹, Marquis P², Piault E²
	¹Mapi Research Trust, Lyon, France, ²MAPI VALUES USA, Boston, MA, USA

CANCER Clinical Outcomes Studies

PCN1	DIAGNOSIS OF HER² PROTEIN OVEREXPRESSION IN PATIENTS WITH BREAST CANCER IN BRAZIL
	Muranaka AH
	Produtos Roche Químicos e Farmacêuticos S.A, São Paulo, SP, Brazil

PCN2	SYSTEMATIC REVIEW OF PALONOSETRON IN CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
	Yeh YC¹, Reddy P¹, Clapp M², Churchill W3
	¹Partners Healthcare, Charlestown, MA, USA, ²Massachusetts General Hospital, Boston, MA, USA, 3Brigham and Women's Hospital, Boston, MA, USA

PCN3	EFFECTIVENESS OF BORTEZOMIB IN MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM AN INTERNATIONAL ELECTRONIC OBSERVATIONAL STUDY
	Delforge M¹, Katodritou E², Zervas K², Sargin D3, Hulin C4, Linderholm M5, Verrou E², Poon V6, Dhawan R6
	1University Hospital Leuven, Leuven, Belgium, ²Theagenion Cancer Center, Thessaloniki, Greece, 3Istanbul University, Istanbul, Turkey, 4CHU NANCY Brabois, Nancy- Brabois, France, 5Linköping University Hospital, Linkoping, Sweden, 6Johnson & Johnson Pharmaceutical Services, Raritan, NJ, USA

PCN4	DATA ANALYSIS WITH GENERALIZED LINEAR MODELS ON LUNG CANCER DATA
	Tang G
	University of Louisville, Louisville, KY, USA

PCN5	META-ANALYSIS ON THE MORBIDITY AND MORTALITY OF CLODRONATE, PAMIDRONATE AND ZOLEDRONATE IN PATIENTS WITH BONE METASTASES
	Machado M¹, Cruz LS², Araujo GT3, Fonseca MCM3
	1University of Toronto, Toronto, ON, Canada, ²Pacific Gateway International College, Toronto, ON, Canada, 3UNIFESP – Federal University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil

PCN6	WITHDRAWN



PCN7	ANALYSIS OF MASTECTOMY IN BREAST CANCER TREATMENT
	Ugiliweneza B
	University of Louisville, Louisville, KY, USA

PCN8	IMPROVED SURVIVAL OF PATIENTS WITH GLIOBLASTOMA MULTIFORME BY TEMOZOLOMIDE AS ADJUVANT THERAPY: A RETROSPECTIVE COHORT STUDY
	Wang TH¹, Wei KC², Wang JD3
	1Taiwan Centers for Disease Control, Taipei, Taiwan, Taiwan, ²Chang-Gung Memorial Hospital, Taipei, Taiwan, Taiwan, 3National Taiwan University, Taipei, Taiwan

PCN9	VALIDITY OF PROPORTIONAL HAZARDS (PH) WEIBULL MODELS FOR ANALYZING PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ (HER2+) METASTATIC BREAST CANCER (MBC) RECEIVING LAPATINIB PLUS CAPECITABINE (L+C) VERSUS CAPECITABINE ONLY (C-ONLY)
	Sofrygin O1, Delea T¹, Tappenden P², Karnon J², Amonkar MM3, Walker M4
	1Policy Analysis Inc. (PAI), Brookline, MA, USA, ²University of Sheffield, Sheffield, UK, 3GlaxoSmithKline, Collegeville, PA, USA, 4GlaxoSmithKline, London, UK

PCN10	CANCER RISK BETWEEN ATORVASTATIN AND SIMVASTATIN IN THE LOUISIANA MEDICAID PATIENTS
	Dubey A¹, Blake S1, Rappaport H1, Cockerham M1, McLarty J², Shi R², Magoun D1
	1The University of Louisiana at Monroe, Monroe, LA, USA, ²LSU Health Sciences Center, Shreveport, LA, USA


CANCER Cost Studies

PCN11	A BUDGET IMPACT ANALYSIS OF IXABEPILONE IN TREATING METASTATIC CANCER PATIENTS
	Whillans F1, Zhang L², Ho J1, Lising A1, Todorova L1, Corey-Lisle P3, Yuan Y²
	1Dymaxium Inc, Toronto, ON, Canada, ²Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Bristol-Myers Squibb, Wallingford, CT, USA

PCN12	USE OF HEALTH RESOURCES IN LUNG CANCER PATIENTS: A BRAZILIAN ANALYSIS IN THE PRIVATE PAYER PERSPECTIVE
	Stefani S¹, Brandalise P²
	1UNIMED and Instituto do Câncer Mãe de Deus, Porto Alegre, RS, Brazil, ²Eli Lilly, Sao Paulo, Sao Paulo, Brazil

PCN13	BUDGET IMPACT ANALYSIS OF SORAFENIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CANADA
	Bhardwaj T, Li B, Hewitt K, Jaszewski B
	Bayer HealthCare, Toronto, ON, Canada

PCN14	A SYSTEMATIC REVIEW OF ECONOMIC ANALYSES OF HER2 TESTING & TRASTUZUMAB THERAPY
	Ferrusi IL¹, Marshall DA1, Kulin NA1, Phillips KA²
	1McMaster University, Hamilton, ON, Canada, ²University of California, San Francisco, San Francisco, CA, USA

PCN15	MODELING THE COST IMPACT OF POSSIBLE CROSS-PROTECTION DIFFERENCES OF TWO CERVICAL CANCER VACCINES IN CANADA USING MULTIPLE PROBABILISTIC SENSITIVITY ANALYSIS
	Demarteau N¹, Anonychuk AM², Standaert B1
	1GlaxoSmithKline Biologicals, Rixensart, Belgium, ²GlaxoSmithKline Canada, Mississauga, ON, Canada

PCN16	COST DIVERSITY OF DRG BASED COLORECTAL CANCER THERAPIES IN HUNGARY
	Jozsa G
	University of West Hungary, Sopron, Hungary

PCN17	WITHDRAWN

PCN18	WITHDRAWN

PCN19	A COST-EFFECTIVENESS ANALYSIS OF LAPATINIB AT A TERTIARY CANCER CENTER
	Lal LS, Arbuckle R
	University of Texas MD Anderson Cancer Center, Houston, TX, USA

PCN20	COST ANALYSIS OF IMMUNOGLOBULIN PROPHYLAXIS IN CHRONIC LYMPHOCYTIC LEUKEMIA
	Conner TM¹, Hoverman JR², Forsyth M3, Rascati KL4
	1Outcomes Research Consulting, Austin, TX, USA, ²Texas Oncology, Dallas, TX, USA, 3US Oncology, Houston, TX, USA, 4The University of Texas at Austin, Austin, TX, USA

PCN21	SYSTEMATIC REVIEW OF COST-EFFECTIVENESS-ANALYSIS STUDIES OF TRASTUZUMAB (HERCEPTIN™) IN TREATMENT OF HER2-POSITIVE BREAST CANCER
	Le QA
	University of Southern California, Los Angeles, CA, USA

PCN22	IS CAPECITABINE A COST-EFFECTIVE ADJUVANT TREATMENT OF STAGE III COLON CANCER IN ONTARIO?
	Orchard MC¹, Hoch J1, Alibhai SMH²
	1University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada

PCN23	COST-EFFECTIVENESS ANALYSIS OF LAPATINIB PLUS CAPECITABINE VERSUS CAPECITABINE ALONE IN THE SECOND LINE TREATMENT FOR BREAST CANCER TREATMENT
	Ejzykowicz F, Hay JW
	University of Southern California, Los Angeles, CA, USA

PCN24	ECONOMIC EVALUATION OF SORAFENIB VERSUS BEST SUPPORTIVE CARE IN ADVANCED RENAL CELL CARCINOMA: AN UPDATED COST-EFFECTIVENESS ANALYSIS
	Gao X¹, Shah S², Reddy P3, Gondek K², Pashos CL3
	1Abt Associates Inc, Bethesda, MD, USA, ²Bayer Pharmaceuticals Corporation, West Haven, CT, USA, 3Abt Associates Inc, Lexington, MA, USA

PCN25	CONSIDERATIONS FOR MODELING THE COST-EFFECTIVENESS OF PREVENTATIVE PROSTATE CANCER TREATMENTS
	Bell CF¹, McDade CL², Black L1, Earnshaw SR², Kattan MW3
	1GlaxoSmithKline, Research Triangle Park, NC, USA, ²RTI Health Solutions, Research Triangle Park, NC, USA, 3Cleveland Clinic Foundation, Cleveland, OH, USA

PCN26	COST-EFFECTIVENESS MODELING OF COLORECTAL CANCER 10 YEARS SCREENING USING COMPUTED TOMOGRAPHIC COLONOGRAPHY VERSUS COLONOSCOPY AND FECAL OCCULT BLOOD TESTS
	Beresniak A¹, Berger G², Grenier P3, Poynard T3, Cadi M3, Lucidarme O3
	1Data Mining International, Geneva, Switzerland, ²University Pierre & Marie Curie, Paris, France, 3University Pierre&Marie Curie, Paris, France

PCN27	COST-EFFECTIVENESS ANALYSIS OF SCREENING SUBJECTS WITH DIFFERENT LEVELS OF RISK FOR HEPATOCELLULAR CARCINOMA IN TAIWAN
	Chang Y
	UT, Houston, TX, USA

PCN28	COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB-CHOP VS. CHOP ON NON-HODGKIN LYMPHOMA PATIENTS IN THE MEXICAN CONTEXT
	Cortina D, Rivera-Hurtado R, Aleman C, Egoavil I, Gonzalez-Michaca L
	Roche Mexico, Mexico City, Mexico

PCN29	SCREENING, PREVENTION, AND TREATMENT OF CERVICAL CANCER - A GLOBAL AND REGIONAL GENERALIZED COST-EFFECTIVENESS ANALYSIS
	Ginsberg GM¹, Tan-Torres Edeger T², Lauer JA², Sepulveda C²
	1Formerly WHO, Geneva 27, Switzerland, 2WHO, Geneva 27, Switzerland

PCN30	COSTS RELATED TO ADVERSE EVENTS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS IN CANADA
	Newton N¹, Goetghebeur MM1, Ouagari KE²
	1BioMedCom Consultants Inc, Montreal, QC, Canada, ²Novartis, Dorval, QC, Canada

PCN31	A PROBABILISTIC DECISION MODEL TO GUIDE OPTIMAL HEALTH POLICY DECISIONS FOR LUNG CANCER SCREENING
	Fenwick E¹, Kulin NA², Marshall DA², Long KH3, Earle C4
	1University of Glasgow, Glasgow, UK, ²McMaster University, Hamilton, ON, Canada, 3Mayo Clinic College of Medicine, Rochester, MN, USA, 4Harvard University, Boston, MA, USA

PCN32	COST-EFFECTIVENESS ANALYSIS OF AN HPV – 16/18 PROPHYLACTIC CERVICAL CANCER VACCINE IN A SETTING OF EXISTING SCREENING IN PORTUGAL - RESULTS FROM A MATHEMATICAL MODEL
	Pereira JA¹, Barbosa C1, Mateus C1, Standaert B²
	1Universidade Nova de Lisboa, Lisboa, Portugal, ²GlaxoSmithKline Biologicals, Rixensart, Belgium

PCN33	COST UTILITY ANALYSIS OF VACCINATION AGAINST HPV IN ISRAEL
	Ginsberg GM¹, Fisher M², Ben-Shahar I3, Bornstein J4
	1Ministry of Health, Jerusalem, Israel, ²Clalit Health Services, Nahariah, Israel, 3Hadassah Hospital, Jerusalem, Israel, 4Western Galilee Hospital, Nahariah, Israel

PCN34	COST-EFFECTIVENESS OF GEFITINIB FOR FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER: A MARKOV MODEL-BASED ANALYSIS
	Liu PH¹, Hu FC², Wang JD1
	1National Taiwan University, Taipei, Taiwan, ²National Taiwan University Hospital, Taipei, Taiwan

PCN35	COST-EFFECTIVENESS ANALYSIS OF DASATINIB FOR THE TREATMENT OF IMATINIB RESISTANT OR INTOLERANT CML PATIENTS IN BRAZIL
	Quissak C¹, Litalien G², Alves MR1
	1Bristol-Myers Squibb, Sao Paulo, Brazil, ²Bristol-Myers Squibb Pharmaceutical, Wallingford, CT, USA

PCN36	COST-MINIMIZATION ANALYSIS OF CAPECITABINE FOR ADVANCED GASTRIC CANCER IN TAIWAN
	Chang CS¹, Chao Y², Chen JS3, Chen LT4, Chung CH5, Hsieh RK6, Hwang WS7, Yang L8, De Reyder F9
	1Changhua Christian Memorial Hospital, Changhua, Taiwan, ²Taipei Veterans General Hospital, Taipei, Taiwan, 3Chang Gung Memorial Hospital, LinKou, Taiwan, 4National Health Research Institutes, Taipei, Taiwan, 5Kaoshiung Medical University Hospital, Kaoshiung, Taiwan, 6Mackay Memorial Hospital, Taipei, Taiwan, 7Chi Mei Medical Center, Tainan, Taiwan, 8Roche Products Ltd, Taipei, Taiwan, 9F. Hoffmann-La Roche AG, Basel, Switzerland

PCN37	PRELIMINARY COST-CONSEQUENCE ANALYSIS OF EPIRUBICIN/CISPLATIN/5FU (ECF) COMPARED TO EPIRUBICIN/CISPLATIN/CAPECITABINE ( ECX ) IN PATIENTS WITH ADVANCED OESOPHAGOGASTRIC CANCER
	Horgan AM, Knox J, Liu G, Bradbury PA, Sahi C, Leighl NB
	Princess Margaret Hospital, Toronto, ON, Canada

PCN38	THE IMPACT OF BREAST CANCER CARE DEVELOPMENT ON MEDICAL AND ECONOMICAL OUTCOMES IN A TOTAL SOCIETAL COST CONTEXT
	Reissell E¹, Herse F1, Väänänen JJP1, Rinta S², Bengtström M², Tamminen N², Parvinen PMT1
	1Nordic Healthcare Group, Helsinki, Finland, ²Pharma Industry Finland, Helsinki, Finland

PCN39	DIFFERENCES IN COLORECTAL CANCER TREATMENT COSTS BY TREATMENT PHASE, CANCER SITE, AND STAGE AT DIAGNOSIS: EVIDENCE FROM LINKED SEER-MEDICARE DATA
	Lang K¹, Lines LM1, Lee DW², Korn JR1, Vanness DJ3, Earle C4, Menzin J1
	1Boston Health Economics, Inc, Waltham, MA, USA, ²GE Healthcare, Waukesha, WI, USA, 3University of Wisconsin-Madison, Madison, WI, USA, 4Harvard University, Boston, MA, USA

PCN40	CONTROLLING FOR POTENTIAL CENSORING BIAS ON DEPENDENT VARIABLES
	Baser O¹, Yuce H²
	1STATinMED Research and University of Michigan, Ann Arbor, MI, USA, ²STATinMED Research and The City University of New York, Brooklyn, NY, USA

PCN41	THE LIFETIME COST OF CERVICAL CANCER IN TAIWAN
	Lang HC, Lan CF
	National Yang-Ming University, Taipei, Taiwan

PCN42	THE ECONOMIC BURDEN OF CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES
	Morlock RJ¹, Atkinson MJ², Pollock MR1, Matthies A1
	1Biogen Idec, San Diego, CA, USA, ²The Aequitas Group Inc, San Diego, CA, USA

PCN43	THE ASSOCIATION OF TUMOR HISTOLOGY WITH FIRST-LINE TREATMENT AND LIFETIME MEDICAL-CARE COSTS AMONG ELDERLY STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH COMMONLY USED DOUBLET THERAPIES AMONG
	Lang K1, Marciniak M², Faries D², Clements KM1, Nyambose J1, Earle C3, Sugarman K², Thompson D1
	1i3 Innovus, Medford, MA, USA, ²Eli Lilly and Company, Indianapolis, IN, USA, 3Harvard University, Boston, MA, USA

PCN44	INCIDENCE AND COSTS OF TREATMENT-RELATED COMPLICATIONS AMONG PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
	Lang K¹, Sussman M1, Friedman M1, Su J², Kan HJ², Mauro D², Menzin J1
	1Boston Health Economics, Inc, Waltham, MA, USA, ²Bristol-Myers Squibb Company, Wallingford, CT, USA

PCN45	RESOURCE UTILIZATION AND COST ESTIMATION OF ADVERSE EVENTS OF NON-SMALL CELL LUNG CANCER TREATMENT IN MEXICAN PATIENTS. RESULTS OF A DELPHI PANEL
	Lopez Mariscal AR¹, Osornio JC², Villalobos R3, Reyes S4, Solano P5, Polanco AC6, Soto H6
	1Regional General Hospital, No.110, IMSS, Guadalajara, Guadalajara, Jalisco, Mexico, ²AstraZeneca, Mexico, Naucalpan, Mexico, 3Mexican National Medical Center, XXI Century (CMN SXXI), IMSS, Mexico City, Mexico, 4Zone General Hospital No. 50 IMSS, San Luis Potosí, Mexico, 5West National Medical Center (CMNO), IMSS, Guadalajara, Jalisco, Mexico, 6AstraZeneca, Mexico, Naucalpan, Mexico, Mexico

PCN46	COMPARISON OF SURGICAL TREATMENT COSTS OF NONMELANOMA SKIN CANCER PATIENTS IN A UNIVERSITY-AFFILIATED PRACTICE
	Wilson L¹, Pregenzer MW1, Bertenthal D², Koplowicz YB1, Chren MM²
	1University of California, San Francisco, San Francisco, CA, USA, ²San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA

PCN47	IMPACT OF HIV INFECTION ON INVASIVE CERVICAL CANCER INCIDENCE AND TREATMENT COSTS IN SOUTH AFRICAN WOMEN
	Vijayaraghavan A¹, Efrusy M², Lindeque G3, Dreyer G3, Santas C4
	1McKesson Corp, Union City, CA, USA, ²McKesson Corp, Palo Alto, CA, USA, 3University of Pretoria, Pretoria, South Africa, 4McKesson Corp, Larkspur, CA, USA

PCN48	LONGITUDINAL COMPARISON ACROSS TREATMENTS, RISK AND AGE OF WORK LOSS COSTS IN PROSTATE CANCER PATIENTS: 10 YEAR PATTERNS
	Wilson L¹, Liang SY1, Kwon P², Tesoro RV3, Sadetsky N1, Greene KL1, Broering JM1, Carroll PR1
	1University of California, San Francisco, San Francisco, CA, USA, ²University of California, San Francisco, San Francsico, CA, USA, 3Loma Linda University Medical Center, Loma Linda, CA, USA

PCN49	THE COST OF TREATING SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES SECONDARY TO BREAST, LUNG, OR PROSTATE CANCER
	Barber B1, Oglesby A¹, Lage MJ², Harrison DJ1, Jun S1
	1Amgen, Inc, Thousand Oaks, CA, USA, ²HealthMetrics Outcomes Research, LLC, Groton, CT, USA

PCN50	THE COST OF TREATING SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA
	Oglesby A¹, Barber B1, Lage MJ², Harrison DJ1, Jun S1
	1Amgen, Inc, Thousand Oaks, CA, USA, ²HealthMetrics Outcomes Research, LLC, Groton, CT, USA

PCN51	DIRECT ECONOMIC BURDEN OF HIGH RISK AND METASTATIC MELANOMA: EVIDENCE FROM THE SEER-MEDICARE LINKED DATABASE
	Davis KL¹, Mitra D1, Kotapati S²
	1RTI Health Solutions, Research Triangle Park, NC, USA, ²Bristol-Myers Squibb Co, Wallingford, CT, USA

PCN52	DIRECT MEDICAL COST OF BREAST CANCER BY STAGE OF CLINICAL DISEASE. A MEXICAN COHORT
	Cortés-Sanabria L¹, Soto-Molina H², De la Cruz-Aguirre K3, Salas-Gonzalez E3, Aguayo-Alcaraz G3, Canales- Muñoz J4
	1Hospital de Especialidades, CMNO, IMSS, Guadalajara, Jalisco, Mexico, ²Universidad Autonoma del Estado de México, Toluca, Mexico, 3Hospital de Ginecología y Obstetricia, CMNO, IMSS, Guadalajara, Jalisco, Mexico, 4HGZ No. 14 "La Paz", IMSS, Guadalajara, Mexico

PCN53	THE BURDEN OF MANAGING PLEURAL EFFUSIONS IN CML PATIENTS POST-IMATINIB FAILURE: A LITERATURE-BASED ECONOMIC ANALYSIS
	Stephens JM¹, Carpiuc KT1, Botteman MF1, Feng W²
	1Pharmerit North America LLC, Bethesda, MD, USA, ²Novartis Pharmaceuticals, Florham Park, NJ, USA

PCN54	A COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS VERSUS SECONDARY PROPHYLAXIS WITH COLONY-STIMULATING FACTOR IN ELDERLY PATIENTS WITH DIFFUSE AGGRESSIVE LYMPHOMA RECEIVING CURATIVE-INTENT CHEMOTHERAPY USING ONTARIO HEALTH ECONOMIC DATA
	Chan KKW¹, Krahn MD², Imrie K3, Alibhai SM²
	1R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, ON, Canada, ²University Health Network, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada

PCN55	A COST-UTILITY ANALYSIS OF FULVESTRANT IN TREATING RECURRENT METASTATIC BREAST CANCER
	Park SY, Kang HH, Noh E, Lee EK
	Sook Myung Women's University, Seoul, South Korea

PCN56	NAB-PACLITAXEL OR DOCETAXEL; AS ALTERNATIVES TO CONVENTIONAL PACLITAXEL FOR THE TREATMENT OF METASTATIC BREAST CANCER (MBC): A COST UTILITY ANALYSIS IN FIVE EUROPEAN COUNTRIES
	Dranitsaris G¹, Lidgren M², Lundkvist J², Coleman R3
	1Augmentium Pharma Consulting, Toronto, ON, Canada, ²I3 Innovus, Stockholm, Sweden, 3Weston Park Hospital, Sheffield, UK

PCN57	COST-UTILITY ANALYSIS OF ADJUVANT GOSERELIN AND ADJUVANT CHEMOTHERAPY IN PATIENTS WITH PREMENOPAUSAL BREAST CANCER
	Cheng TF
	Shin Kong Wu Ho-Su Memorial Hospital, Taipei City, Taiwan

PCN58	A COST UTILITY ANALYSIS OF ERLOTINIB IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
	Bradbury PA¹, Jang R1, Isogai P², Ng R1, Mittmann N², Evans W3, Shepherd FA1, Leighl NB1
	1Princess Margaret Hospital/ University Health Network, Toronto, ON, Canada, ²HOPE Research Centre, Toronto, ON, Canada, 3Juravinski Cancer Centre, Hamilton, ON, Canada

PCN59	TIME COSTS AND OUT-OF-POCKET COSTS OF PROSTATE CANCER SURVIVORS IN ONTARIO, CANADA
	Carcone SM¹, Bremner KE1, Kowgier ME², Krahn MD1
	1University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada

PCN60	EFFECT OF DEMOGRAPHIC FACTORS AND SOCIAL ECONOMIC VARIABLES ON HEALTH CARE RESOURCE UTILIZATION AND EXPENDITURE FOR BREAST CANCER PATIENTS USING MEPS 2004
	Zhan L, Nair RR, Black CD, Pinto SL, Holiday-Goodman M
	The University of Toledo, Toledo, OH, USA

CANCERPatient-Reported Outcomes
PCN61	EARLY DISCONTINUATION OF ADJUVANT ENDOCRINE TREATMENT OF BREAST CANCER
	Bowen KL, Owerbach J
	Excellus BlueCross BlueShield, Rochester, NY, USA

PCN62	LEUPROLIDE ACETATE PERSISTENCE VARIES BY AGE IN PATIENTS WITH PROSTATE CANCER
	Fuldeore MJ¹, Brook RA², Smeeding J3, Dabbous OH4
	1TAP Pharmaceuticals Products Inc, Lakeforest, IL, USA, ²The JeSTARx Group, Newfoundland, NJ, USA, 3The JeSTARx Group, Dallas, TX, USA, 4TAP Pharmaceutical Products Inc, Lakeforest, IL, USA

PCN63	RACIAL DIFFERENCES IN MEDICATION ADHERENCE TO ADJUVANT HORMONAL THERAPY IN MEDICAID ENROLLED WOMEN WITH PRIMARY BREAST CANCER: A COMPARISON USING TWO ESTIMATION METHODOLOGIES
	Bhosle MJ1, Anderson RT², Balkrishnan R¹
	1The Ohio State University College of Pharmacy, Columbus, OH, USA, ²Wake Forest University School of Medicine, Winston Salem, NC, USA

PCN64	CLINICAL AND DEMOGRAPHIC PREDICTORS OF QUALITY OF LIFE IN PROSTATE CANCER SURVIVORS
	Bremner KE¹, Carcone SM1, Kowgier ME², Alibhai S1, Laporte A², Naglie G3, Krahn MD1
	1University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, 3Toronto Rehabilitation Institute, Toronto, ON, Canada

PCN65	HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH STAGE III OR IV FOLLICULAR LYMPHOMA RECEIVING 90Y-IBRITUMOMAB TIUXETAN FOLLOWING FIRST-LINE CHEMOTHERAPY
	Gondek K1, Valderrama A², Rohatiner A3, Bischof-Delaloye A4, Radford J5, Morschhauser F6, Van Hoof A7, Putz B8, Kunz M8, Hagenbeek A9
	1Bayer Healthcare Pharmaceuticals Inc, West Haven, NJ, USA, ²Bayer Healthcare Pharmaceuticals Inc, Pine Brook, NJ, USA, 3St. Bartholomew's Hospital, London, UK, 4Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, 5Christie Hospital, Manchester, UK, 6Hospital Huriez, Lille, France, 7General Hospital St. Jan, Brugge, Belgium, 8Bayer Shering Pharma, Berlin, Germany, 9University Medical Center Utrecht, Utrecht, Netherlands

PCN66	WITHDRAWN

PCN67	WITHDRAWN

PCN68	HOUSEHOLD INCOME AS A PREDICTOR OF PSYCHOLOGICAL WELL-BEING AMONG LONG-TERM COLORECTAL CANCER SURVIVORS
	Lundy JJ¹, Coons SJ1, Wendel C², Hornbrook MC3, Herrinton LJ4, Grant M5, Krouse RS²
	1University of Arizona, Tucson, AZ, USA, ²Southern Arizona Veterans Affairs Health Care System, Tucson, AZ, USA, 3Kaiser Permanente Northwest, Portland, OR, USA, 4Kaiser Permanente Northern California, Oakland, CA, USA, 5City of Hope National Medical Center, Duarte, CA, USA

PCN69	QUALITY OF LIFE IMPACT OF HOT FLUSHES IN MEN RECEIVING TREATMENT FOR PROSTATE CANCER
	Nixon A¹, Swinburn P1, Lloyd A1, Connolly MP²
	1Oxford Outcomes Ltd, Oxford, Oxon, UK, ²Ferring International Center, Saint-Prex, Switzerland

PCN70	THE IMPACT OF HODGKIN'S LYMPHOMA ON HEALTH RELATED QUALITY OF LIFE
	Morlock RJ1, Atkinson MJ², Saville W1, Pollock MR¹
	1Biogen Idec, San Diego, CA, USA, ²The Aequitas Group Inc, San Diego, CA, USA

PCN71	SOCIETAL PREFERENCES (UTILITIES) FOR ADVANCED MELANOMA HEALTH STATES IN THE UNITED KINGDOM (UK) AND AUSTRALIA
	Szabo SM¹, Beusterien KM², Kotapati S3, Mukherjee J3, Hoos A3, Levy AR1
	1Oxford Outcomes Ltd, Vancouver, BC, Canada, ²Oxford Outcomes Ltd, Bethesda, MD, USA, 3Bristol-Myers Squibb Co, Wallingford, CT, USA

PCN72	DISABILITY AND HEALTH-RELATED QUALITY OF LIFE IN LONG-TERM SURVIVORS OF CANCER IN CHILDHOOD IN BRAZIL: AN ASSESSMENT OF THE CONSTRUCT VALIDITY OF THE HEALTH UTILITIES INDEX (HUI3)
	Horsman JR¹, Shimoda S², Furlong W3, Barr RD4, De Camargo B²
	1Health Utilities Inc, Dundas, ON, Canada, ²Centro De Tratamento E Pesquisa, Sao Paulo, SP, Brazil, 3McMaster University and Health Utilities Inc, Hamilton, ON, Canada, 4McMaster University, Hamilton, ON, Canada

PCN73	COMPARISON OF SURVIVAL QUALITY FROM TWO TREATMENT STRATEGIES FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD: DANA-FARBER CANCER INSTITUTE (DFCI) AND BERLIN-FRANKFURT-MUNSTER (BFM)
	De Pauw S¹, Rae CS1, Furlong W², Gelber RD3, Moghrabi A4, Naqvi A5, Jankovic M6, Samson Y7, Barr RD1
	1McMaster University, Hamilton, ON, Canada, ²McMaster University and Health Utilities Inc, Hamilton, ON, Canada, 3Harvard University, Boston, MA, USA, 4Sainte-Justine Hospital, University of Montreal, Montreal, QC, Canada, 5University of Toronto, Toronto, ON, Canada, 6Ospedalo Nuovo S. Gerardo, Monza, MI, Italy, 7Centre Hospitalier Universitaire de Quebec, Sainte-Foy, QC, Canada

PCN74	WILL KNOWLEDGE OF GENETIC RISK FOR CANCER INFLUENCE QUALITY OF LIFE AND SCREENING BEHAVIOR? FINDINGS FROM A POPULATION-BASED STUDY
	Ramsey SD¹, Blough DK², Clarke L3, McDermott CL1, Bennett R², Burke W², Newcomb PA1
	1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, ²University of Washington, Seattle, WA, USA, 3Cornerstone Systems Northwest, Inc, Lynden, WA, USA

PCN75/ PR2:	BURDEN OF IMMUNE THROMBOCYENIC PURPURA ON HEALTH-RELATED QUALITY OF LIFE
	Mathias S¹, Tarantino M², Guo M3, Gao S3
	1Health Outcomes Solutions, Winter Park, FL, USA, ²University of Illinois College of Medicine-Peoria, Peoria, IL, USA, 3Amgen, Thousand Oaks, CA, USA

PCN76	IMPACT OF SILDENAFIL ON MARITAL AND SEXUAL ADJUSTMENT IN PATIENTS AND THEIR PARTNERS AFTER RADIOTHERAPY AND SHORT-TERM ANDROGEN SUPPRESSION FOR PROSTATE CANCER: ANALYSIS OF RTOG 0215
	Bryan CJ¹, James JL², Pisansky TM3, Corbett T4, Jha N5, Swanson R6, Hartford A7, Sandler H8, Berk L9, Kachnic L10, Bruner DW1
	1University of Pennsylvania, School of Nursing, Philadelphia, PA, USA, ²Radiation Therapy Oncology Group Statistical Center, Philadelphia, PA, USA, 3Mayo Clinic, Rochester, MN, USA, 4Juravinski Cancer Centre, Hamilton, ON, Canada, 5Cross Cancer Institute, Edmonton, AB, Canada, 6Natalie Warren Bryant Cancer Center, Tulsa, OK, USA, 7Dartmouth Hitchcock Medical Center, Lebanon, NH, USA, 8University of Michigan, Ann Arbor, MI, USA, 9H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA, 10Boston University Medical Center, Boston, MA, USA

PCN77	A SYSTEMATIC REVIEW OF BREAST CANCER UTILITY WEIGHTS
	Brennan VK, Wolowacz S
	RTI Health Solutions, Manchester, UK

PCN78	DERIVATION OF UTILITY VALUES FROM EORTC QLQC30 IN LUNG CANCER
	Jang RW¹, Mittmann N², Isogai P², Bradbury PA³, Leigh^l NB¹
	1Princess Margaret Hospital, Toronto, ON, Canada, ²HOPE Research Centre, Toronto, ON, Canada, 3Princess Margaret Hospital/ University Health Network, Toronto, ON, Canada

PCN79	METHODS FOR ASSESSING QUALITY OF LIFE IN CANCER PATIENTS EXPERIENCING COMPLICATIONS: OSTEONECROSIS OF THE JAW PILOT STUDY
	Miksad R¹, Woo SB², Dodson T3, Treister NS², Maytal G3, August M3, Akinyemi O3, Bihrle MM4, Swan JS3
	1Beth Israel Deaconess Medical Center / Institute for Technology Assessment / Harvard University, Boston, MA, USA, ²Brigham and Women's Hospital/ Harvard University, Boston, MA, USA, 3Massachusetts General Hospital/ Harvard University, Boston, MA, USA, 4Massachusetts General Hospital/ Beth Israel Deaconess Medical Center/ Harvard University, Boston, MA, USA

PCN80	COMPARISON OF STANDARD GAMBLE UTILITIES AND VISUAL ANALOG SCALE VALUES IN AN OVARIAN CANCER PATIENT AND ONCOLOGIST STUDY OF CANCER TREATMENT PREFERENCES
	Hess LM, Skrepnek GH, Armstrong EP, Malone DC
	University of Arizona, Tucson, AZ, USA

PCN81	INJECTABLE CHEMOTHERAPY VS CAPECITABINE: PREFERENCE IN BRAZILIAN PATIENTS
	Boscatti FHG
	Produtos Roche Químicos e Farmacêuticos S.A, São Paulo, SP, Brazil

PCN82	PATIENT-REPORTED OUTCOMES IN ELDERLY VS. YOUNG PATIENTS WITH ADVANCED RENAL CELL CARCINOMA TREATED WITH SORAFENIB VS. PLACEBO
	Shah S¹, Cella D², Gondek K1, Cihon F1, Anderson S1
	1Bayer Healthcare Pharmaceuticals, West Haven, CT, USA, ²Evanston Northwestern Healthcare, Evanston, IL, USA

CANCERHealth Care Use & Policy Studies
PCN83	KNOWLEDGE OF THE BRAZILIAN POPULATION ABOUT COLORECTAL CANCER
	Santos MCCS¹, Boscatti FHG²
	1Produtos Roche Químicos e Farmacêuticos S.A. (Roche Brazil), São Paulo, SP, Brazil, ²Produtos Roche Químicos e Farmacêuticos S.A, São Paulo, SP, Brazil

PCN84	CLINICAL AND ECONOMIC OUTCOMES FOR CANCER CHEMOTHERAPY PATIENTS WHEN INITIATED ON ERYTHROPOIESIS-STIMULATING AGENTS (ESA) AT BASELINE (BL) HEMOGLOBIN (HB) <10G/DL
	Burton T1, Larholt K1, Hoaglin D1, Pashos CL1, Bookhart B², Corral M², Mckenzie RS², Piech CT²
	1Abt Associates Inc, Lexington, MA, USA, ²Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA

PCN85	EFFECT OF AGE AND PLACE OF RESIDENCE ON COLORECTAL CANCER TREATMENTS IN NEBRASKA CANCER REGISTRY FROM 1998 TO 2003
	Sankaranarayanan J¹, Watanabe-Galloway S², Sun J1, Qiu F1, Boilesen E1, Thorson AG1
	1University of Nebraska Medical Center, Omaha, NE, USA, ²Univeristy of Nebraska Medical Center, Omaha, NE, USA

PCN86	DRUG UTILIZATION AND COST CONSIDERATIONS OF ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
	Laliberte F1, Mckenzie RS², Lefebvre P1, Bookhart B², Vekeman F3, Duh M4, Piech CT²
	1Groupe d'analyse, Ltee, Montreal, QC, Canada, ²Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA, 3Groupe d'Analyse, Ltée, Montréal, QC, Canada, 4Analysis Group, Inc, Boston, MA, USA

PCN87	USE OF PHARMACOECONOMIC MESSAGES IN ONCOLOGY PROMOTIONAL MATERIALS
	Kalpas E, Subrahmanian T, Stern L
	Analytica International, New York, NY, USA

PCN88	FACTORS ASSOCIATED WITH THE PRESCRIPTION OF ADJUVANT HORMONAL THERAPIES AMONG MEDICAID ENROLLEES WITH BREAST CANCER
	McLaughlin J¹, Paskett E1, Anderson RT², Balkrishnan R3
	1The Ohio State University, Columbus, OH, USA, ²Wake Forest University School of Medicine, Winston Salem, NC, USA, 3The Ohio State University College of Pharmacy, Columbus, OH, USA

PCN89	DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN A MANAGED CARE CANCER POPULATION RECEIVING CHEMOTHERAPY
	Gosselin A1, Lafeuille MH², Bookhart B3, Lefebvre P², Mckenzie RS3, Vekeman F1, Piech CT3
	1Groupe d'Analyse, Ltée, Montréal, QC, Canada, ²Groupe d'analyse, Ltee, Montreal, QC, Canada, 3Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA

PCN90	EFFECT OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME ON THE COVERAGE OF WOMEN UNDER THE AGE OF 25 YEARS
	Boncz I1, Bódis J1, Sebestyén A², Betlehem J1, Gulacsi L3, Ágoston I1, Nagy Z4, Kriszbacher I1
	1University of Pécs, Pécs, Hungary, ²National Health Insurance Fund Administration, Budapest, Hungary, 3Corvinus University of Budapest, Budapest, Hungary, 4Health Insurance Supervisory Authority, Budapest, Hungary

PCN91	A PREVALENCE-BASED ECONOMIC ANALYSIS OF THE GROWTH IN CANCER TREATMENT SPENDING IN THE UNITED STATES
	Lerner J¹, Patel ST², Goss T1
	1Covance Market Access Services, Gaithersburg, MD, USA, ²Covance Market Access Services Inc, Gaithersburg, MD, USA

PCN92	THE WAR ON CANCER: AN ECONOMIC EVALUATION OF RECENT GAINS IN CANCER SURVIVAL
	Sun E¹, Lakdawalla D1, Reyes C², Goldman D1, Philipson T3, Jena A1
	1RAND, Santa Monica, CA, USA, ²Genentech, South San Francisco, CA, USA, 3University of Chicago, Chicago, IL, USA

PCN93	THREE SCIENTIFIC PARADIGMS IN HEALTH TECHNOLOGY ASSESSMENT: EXPERIENCES OF THE COMMITTEE TO EVALUATE DRUGS IN ONTARIO, CANADA
	Krahn MD¹, Bell C², Evans W3, Berry S4, Zarnke K5, Lum-Wilson N6
	1University Health Network, Toronto, ON, Canada, 2St. Michael's Hospital, Toronto, ON, Canada, 3Juravinski Cancer Centre, Hamilton, ON, Canada, 4Toronto-Bayview Regional Cancer Centre, Toronto, ON, Canada, 5London Health Sciences Centre, London, ON, Canada, 6Ministry of Health and Long-Term Care, Toronto, ON, Canada

PCN94	PREDICTORS OF TREATMENT CHOICE IN HIGH RISK AND METASTATIC MELANOMA: EVIDENCE FROM LINKED ELECTRONIC MEDICAL RECORDS AND ADMINISTRATIVE CLAIMS DATA
	Kotapati S¹, Mitra D², Davis KL², Iloeje U3
	1Bristol-Myers Squibb Co, Wallingford, CT, USA, ²RTI Health Solutions, Research Triangle Park, NC, USA, 3Bristol-Myers Squibb, Wallingford, CT, USA

PCN95	CHANGE IN THE USE OF BREAST CONSERVING SURGERY BEFORE AND AFTER GUIDELINE PUBLICATION IN JAPAN
	Fukuda H, Imanaka Y, Ishizaki T
	Kyoto University, Kyoto, Japan

PCN96	REAL WORLD TREATMENT PATTERNS IN HIGH RISK OR METASTATIC MELANOMA: EVIDENCE FROM THE SEER-MEDICARE LINKED DATABASE
	Mitra D¹, Davis KL1, Kotapati S², Iloeje U²
	1RTI Health Solutions, Research Triangle Park, NC, USA, ²Bristol-Myers Squibb Co, Wallingford, CT, USA

GASTROINTESTINAL DISORDERS Clinical Outcomes Studies
PGI1	HETEROGENEITY ACROSS RANDOMIZED CONTROLLED TRIALS OF PROTON-PUMP INHIBITORS IN NIGHTTIME GERD: A SYSTEMATIC REVIEW
	Kothawala P¹, Lange SM², McGuigan JE3, Aguilar D1, Morgenstern D4, Yan N4, Dean BB1
	1Cerner LifeSciences, Beverly Hills, CA, USA, ²Mayo Clinic Jacksonville, Jacksonville, FL, USA, 3University of Florida, Gainesville, FL, USA, 4Wyeth Pharmaceuticals, Collegeville, PA, USA

PGI2	HOSPITALIZATIONS FOR GASTROINTESTINAL EVENTS AMONG USERS OF COX 2 INHIBITORS COMPARED WITH TRADITIONAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS WITH PROTON-PUMP INHIBITORS
	Van der Linden MW¹, Kuipers E², Sukel M3, Herings RM3, Gaugris S4
	1PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands, ²Erasmus University Medical Center, Rotterdam, Netherlands, 3PHARMO Institute, Utrecht, Netherlands, 4Merck & Co., Inc, Whitehouse Station, NJ, USA

GASTROINTESTINAL DISORDERS Cost Studies
PGI3	COST OF PATIENT CARE IN PATIENTS WITH ULCERATIVE COLITIS IN BRAZIL: PUBLIC HEALTH PERSPECTIVE
	Araujo G, Fonseca M
	Axia.Bio Consulting, São Paulo, Brazil

PGI4	A BRAZILIAN CROSS SECTIONAL STUDY TO EVALUATE HOSPITALIZATION AMONG MODERATE AND SEVERE CROHN`S DISEASE PATIENTS
	Araujo G, Fonseca M
	Axia.Bio Consulting, São Paulo, Brazil

PGI5	COST-EFFECTIVENESS OF NATALIZUMAB IN CROHN'S DISEASE PATIENTS WHO HAVE FAILED ANTI-TNF ALPHA THERAPY
	Panjabi S¹, Niecko T², Hass SL1, Lacey L3, Spencer MD4
	1Elan Pharmaceuticals Inc, South San Francisco, CA, USA, ²Niecko Health Economics, LLC, Escondido, CA, USA, 3LaceySolutions Ltd, Skerries, Co. Dublin, Ireland, 4Elan Pharma, Stevenage, Hertfordshire, UK

PGI6	COST-EFFECTIVENESS RECOMBINANT FACTOR VIIA USE IN ORTHOTOPIC LIVER TRANSPLANT
	Schoenhaus R, Awdishu L, Daniels C
	University of California at San Diego, San Diego, CA, USA

PGI7	COST EFFECTIVENESS ANALYSIS OF HELICOBACTER PYLORI SCREENING IN PREVENTION OF GASTRIC CANCER IN CHINESE
	Xie F¹, Luo N², Blackhouse G1, Goeree RA1, Lee HP²
	1McMaster University, Hamilton, ON, Canada, ²National University of Singapore, Singapore, Singapore

PGI8	WITHDRAWN

PGI9	DEVELOPMENT OF A CLAIMS-BASED MARKOV MODEL FOR CROHN'S DISEASE
	Malone DC¹, Thompson HC², Van Den Bos J3, Popp J², Draaghtel K3, Rahman MI²
	1University of Arizona, Tucson, AZ, USA, ²Centocor, Inc, Horsham, PA, USA, 3Milliman, Inc, Denver, CO, USA

PGI10	DOES THE DOSING FREQUENCY OF PROTON PUMP INHIBITORS (PPIS) AFFECT SUBSEQUENT RESOURCE UTILIZATION AND COSTS AMONG PATIENTS DIAGNOSED WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD)?
	Boulanger L¹, Mody RR², Bao Y1, Ancukiewicz V1, Russell MW1
	1Abt Associates Inc, Lexington, MA, USA, ²TAP Pharmaceutical Products Inc, Lake Forest, IL, USA

PGI11	DIRECT COST SIMILARITIES BY POINT OF SERVICE FOR PERSONS WITH CONSTIPATION OR IRRITABLE BOWEL SYNDROME PLUS CONSTIPATION IN THE SIX MONTHS BEFORE AND AFTER DIAGNOSIS: AN EMPLOYER PERSPECTIVE
	Kleinman NL¹, Brook RA², Melkonian AK3, Evans SD4, Talley NJ5, Baran RW6
	1HCMS Group, Paso Robles, CA, USA, ²The JeSTARx Group, Newfoundland, NJ, USA, 3The HCMS Group, Cheyenne, WY, USA, 4Sierra Health Services, Las Vegas, NV, USA, 5Mayo Clinic College of Medicine Jacksonville, FL, Rochester, MN, USA, 6Takeda Global Research and Development Center, Inc, Deerfield, IL, USA

PGI12	HEALTH CARE COSTS RELATED TO THE TREATMENT OF CROHN'S DISEASE
	Tian H¹, Marehbian J1, Hass SL², Panjabi S², Arrighi HM², Chen JY1
	1Health Benchmarks Inc, Woodland Hills, CA, USA, ²Elan Pharmaceuticals Inc, South San Francisco, CA, USA

PGI13	DIRECT ECONOMIC BURDEN OF CHRONIC HEPATITIS C VIRUS IN A LARGE MANAGED CARE POPULATION
	Davis KL¹, Mitra D1, Medjedovic J², Beam C3, Rustgi V4
	1RTI Health Solutions, Research Triangle Park, NC, USA, ²Novartis Pharma AG, Basel, Switzerland, 3Human Genome Sciences, Inc, Rockville, MD, USA, 4Georgetown University Medical Center, Fairfax, VA, USA

PGI14	COST-EFFECTIVENESS OF PROTON PUMP INHIBITORS FOR PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE: SHOULD EMERGING SAFETY CONCERNS AFFECT THERAPEUTIC DECISION-MAKING?
	Ryan PB, Biddle AK
	University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PGI15	ECONOMIC EVALUATION OF PROTON PUMP INHIBITORS, RELATIVE TO ALTERNATIVE GASTROINTESTINAL PROPHYLAXIS AGENTS, FOR PREVENTION OF GI COMPLICATIONS IN ELDERLY PATIENTS TAKING NON-SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSNSAIDS)
	Cameron C¹, Van Zanten S², Sketris IS1, Skedgel C3, Flowerdew G1
	1Dalhousie University, Halifax, NS, Canada, ²University of Alberta, Edmonton, AB, Canada, 3Capital Health Nova Scotia, Halifax, NS, Canada

GASTROINTESTINAL DISORDERS Patient-Reported Outcomes
PGI16	DISPARITIES IN MEDICATION UTILIZATION AND COMPLIANCE FOR GASTRO-ESOPHAGEAL REFLUX DISEASE: A POPULATION-BASED STUDY
	Yuen EJ¹, Toner R², Cobb N², Katz PO3, Goldfarb NI²
	1Jefferson Medical College, Philadelphia, PA, USA, ²Thomas Jefferson University, Philadelphia, PA, USA, 3Albert Einstein Med Center, Philadelphia, PA, USA

PGI17	ADHERENCE TO INFLIXIMAB MAINTENANCE THERAPY AND ITS IMPACT ON HOSPITALIZATION OF PATIENTS WITH CROHN'S DISEASE
	Kane SV¹, Wu E², Chen L², Yu AP², Tsaneva M², Chao J3, Mulani P3
	1The Mayo Clinic, Rochester, MN, USA, ²Analysis Group, Inc, Boston, MA, USA, 3Abbott Laboratories, Abbott Park, IL, USA

PGI18	LINGUISTIC VALIDATION OF THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE (IBDQ) IN 35 LANGUAGES
	Muller S¹, Jan Irvine E², Gathany T3
	1Mapi Research Institute, Lyon, France, ²St Michael's Hospital, Toronto, ON, Canada, 3Johnson & Johnson Pharmaceutical, Malvern, PA, USA

PGI19	DEVELOPMENT OF AN HIV-RELATED, DIARRHEA IMPACT, PATIENT REPORTED OUTCOME (PRO) QUESTIONNAIRE
	Ernst J1, Ortiz R², Schrager H3, Hanlon J4, Kite A4, Golman D5
	1AIDS Community Research Initiative of America (ACRIA), New York, NY, USA, ²Orlando Immunology Center, Orlando, FL, USA, 3Community Research Initiative of New England (CRINE), Boston, MA, USA, 4QualityMetric Health Outcomes Solutions, Lincoln, RI, USA, 5Napo Pharmaceuticals, South San Francisco, CA, USA

PGI20	PARTIAL RESPONDERS TO PPI TREATMENT; HOW DO THEY DIFFER FROM OTHER GERD PATIENTS IN TERMS OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH CARE RESOURCE UTILISATION? -A DATABASE ANALYSIS
	Toghanian S
	University of Gothenburg, Gothenburg, Sweden

PGI21	A COMPARISON OF TEST-RETEST RELIABILITY OF SELF-REPORTED SF-36, WHOQOL, AND EQ-5D QUESTIONNAIRES BASED ON DIFFERENT ADMINISTRATION APPROACHES
	Lin YJ¹, Chen CH², Hsieh CL1, Wang JD1
	1National Taiwan University, Taipei, Taiwan, ²National Taiwan University Hospital, Taipei, Taiwan

PGI22	VALIDATION OF A NOCTURNAL GASTROESOPHAGEAL REFLUX DISEASE (GERD) SYMPTOM SEVERITY AND IMPACT INSTRUMENT
	Harding G¹, Roberts L1, Spiegel BM², Mody RR3, Revicki D1, Kahrilas PJ4, Camilleri ML5, Walter K1
	1United BioSource Corporation, Bethesda, MD, USA, ²VA Greater Los Angeles Healthcare System; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 3TAP Pharmaceutical Products Inc, Lake Forest, IL, USA, 4Northwestern University, Chicago, IL, USA, 5Mayo Clinic, Rochester, MN, USA

PGI23	PATIENT REPORTED PREVALENCE AND SEVERITY OF CONSTIPATION IN HOSPICE PATIENTS
	Strassels SA¹, Maxwell T², Iyer S3
	1University of Texas at Austin College of Pharmacy, Austin, TX, USA, ²excelleRx, Inc, Philadelphia, PA, USA, 3Wyeth Research, Collegeville, PA, USA

GASTROINTESTINAL DISORDERS Health Care Use & Policy Studies
PGI24	RACIAL, SOCIAL, AND ECONOMIC DISPARITIES IN KNOWLEDGE AND CARE SEEKING BEHAVIORS FOR GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)
	Yuen EJ¹, Toner R², Cobb N², Katz PO3, Goldfarb NI²
	1Jefferson Medical College, Philadelphia, PA, USA, ²Thomas Jefferson University, Philadelphia, PA, USA, 3Albert Einstein Med Center, Philadelphia, PA, USA

PGI25	COSTS OF A PRIOR AUTHORIZATION ON LUBIPROSTONE FOR ELDERLY (AGE > 65) PATIENTS WITH CHRONIC CONSTIPATION IN A MEDICARE PART D POPULATION
	Lobo F¹, Pokras S², Smith TW², Thomas S1, Sill B1, Baum C1
	1Takeda Pharmaceuticals North America, Deerfield, IL, USA, ²IMS Consulting, Falls Church, VA, USA

PGI26	FINANCIAL IMPACT OF LIFTING A PRIOR AUTHORIZATION ON LUBIPROSTONE FOR CHRONIC CONSTIPATION PATIENTS IN A COMMERCIAL MANAGED CARE POPULATION (AGE < 65 YEARS)
	Lobo F¹, Pokras S², Smith TW², Thomas S1, Sill B1, Baum C1
	1Takeda Pharmaceuticals North America, Deerfield, IL, USA, ²IMS Consulting, Falls Church, VA, USA

PGI27	INFLAMMATORY BOWEL DISEASES (IBD) PATIENTS PROFILE: FACTS EXTRACTED FROM A MULTICENTER RETROSPECTIVE STUDY
	Araujo G, Fonseca M
	Axia.Bio Consulting, São Paulo, Brazil

PGI28	IMPORTANT FACTORS WHEN CONSIDERING TREATMENT FOR ULCERATIVE COLITIS
	Waters H, Kelly J, Rahman MI
	Centocor, Inc, Horsham, PA, USA

INFECTION Clinical Outcomes Studies

PIN1	TREATMENT OF HEPATITIS C INFECTION FOR CURRENT OR FORMER SUBSTANCE ABUSERS IN A COMMUNITY SETTING
	John-Baptiste A¹, Varenbut M², Lingley M3, Nedd-Roderique T1, Teplin D², Daiter J², Krahn MD4
	1Toronto General Hospital, Toronto, ON, Canada, ²Ontario Addiction Treatment Centres, Richmond Hill, ON, Canada, 3Round Trip Travel Health Clinic, Markham, ON, Canada, 4University Health Network, Toronto, ON, Canada

PIN2	A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF PEGYLATED INTERFERON, LAMIVUDINE, ADEFOVIR AND ENTECAVIR FOR THE TREATMENT OF HEPATITIS B.
	Woo GW¹, Sherman M², Einarson TR1, Ungar WJ3, Krahn MD²
	1University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, 3The Hospital for Sick Children, Toronto, ON, Canada

PIN3	DATA MINING PHYSICIAN DECISION AND INVESTIGATING TREATMENT OPTIONS OF OSTEOMYELITIS
	Zahedi H
	University of Louisville, Louisville, KY, USA

PIN4	ANTIMICROBIAL RESISTANCE PREVALENCE OF ENTEROCOCCI FROM BOGOTA, COLOMBIA HOSPITALS 2001-2006.
	Lemos EV¹, Einarson TR², Jimenez P3, Eslava J1, Gualtero S1
	1National University of Colombia, Bogota, Cundinamarca, Colombia, ²University of Toronto, Toronto, ON, Canada, 3Instituto Nacional de Cancerologia, Bogota, Cundinamarca, Colombia

PIN5	INTEREST OF MULTI-CRITERIA MODELING APPROACH IN ASSESSMENT OF YELLOW FEVER EPIDEMIC RISK
	Beresniak A¹, Briand S², N'Guyen T², Perea W²
	1Data Mining International, Geneva, Switzerland, ²World Health Organization, Geneva, Switzerland

PIN6	WITHDRAWN

PIN7	MRSA: INVESTIGATING THE DANGEROUS HOSPITAL INFECTION
	Glassford RJ
	University of Louisville, Louisville, KY, USA

INFECTION Cost Studies
PIN8	BUDGET IMPACT OF ADDING DORIPENEM TO A HOSPITAL FORMULARY
	Kongnakorn T1, Merchant S², Akhras K3, Ingham M3, Mody S4, Mwamburi M5, Caro JJ1
	1United BioSource Corporation, Concord, MA, USA, ²Johnson & Johnson Pharmaceutical Services, LLC, Raritan, NJ, USA, 3Johnson & Johnson Pharmaceutical Services, L.L.C, Raritan, NJ, USA, 4Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 5United Biosource Corporation, Medford, MA, USA

PIN9	THE WORKFORCE AND COST IMPLICATIONS OF SUBSTITUTING NURSES AND PHARMACISTS FOR DOCTORS IN THE FOLLOW-UP OF PATIENTS WITH AIDS ON ANTIRETROVIRAL THERAPY IN UGANDA
	Babigumira JB¹, Castelnuovo B², Lamorde M², Muwanga A², Kambugu A², Easterbrook P², Garrison L1
	1University of Washington, Seattle, WA, USA, ²Infectious Diseases Institute, Kampala, Uganda

PIN10	COMPARATIVE (POSACONAZOLE VS. OTHER SYSTEMIC ANTIFUNGALS) ALL-CAUSE MORTALITY AND COST ANALYSIS IN PATIENTS WITH REFRACTORY INVASIVE ASPERGILLOSIS
	Tahami Monfared AA¹, Rajagopalan S², Danna R3, Papadopoulos G4
	1Schering-Plough Canada Inc, Kirkland, QC, Canada, 2Med Data Analytics, Inc, Williamsville, NY, USA, 3META Associates, Morristown, NJ, USA, 4Schering-Plough Corp, Kenilworth, NJ, USA

PIN11	COST SAVINGS FROM REDUCED HIV INCIDENCE ESTIMATES
	Flavin JK, Becker RV
	Dymaxium Inc, Toronto, ON, Canada

PIN12	PHARMACOECONOMIC ANALYSIS BASED ON GUIDELINES FOR TREATING MILD DIABETIC FOOT INFECTIONS: A DECISION TREE MODEL FOR COLOMBIA
	Lemos EV¹, Castañeda C², Chow I3, Marr P3, Machado M3, Einarson TR3
	1National University Of Colombia, Bogota, Cundinamarca, Colombia, 2Profamilia, Bogota, Cundinamarca, Colombia, 3University of Toronto, Toronto, ON, Canada

PIN13	ECONOMIC EVALUATION OF POSACONAZOLE VS. STANDARD AZOLE THERAPY IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH PROLONGED NEUTROPENIA IN CANADA
	Tahami Monfared AA¹, O'Sullivan AK², Papadopoulos G3
	1Schering-Plough Canada Inc, Kirkland, QC, Canada, ²i3 Innovus, Medford, MA, USA, 3Schering-Plough Corp, Kenilworth, NJ, USA

PIN14	COST-EFFECTIVENESS OF PEGINTERFERON-ALFA-2A (40 KD) ASSOCIATED WITH RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C IN BRAZIL UNDER THE PRIVATE HEALTH CARE SYSTEM
	Parana R¹, Sette H², Pessoa M3, Crespo D4, Barros F5, Santos EA6, Saggia MG6, Tatsch F6, Simoes R6
	1Universidade Federal da Bahia, Salvador, BA, Brazil, 2Universidade de São Paulo, Sao Paulo, SP, Brazil, 3Instituto de Infectologia Emílio Ribas, Sao Paulo, SP, Brazil, 4Universidade Federal do Para, Belem, PA, Brazil, 5Universidade Federal de Pernambuco, Recife, PE, Brazil, 6Roche Brazil, Sao Paulo, SP, Brazil

PIN15	ECONOMIC EVALUATION OF TIPRANAVIR IN THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
	Risebrough N¹, Simpson KN², Mittmann N1
	1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2Medical University of South Carolina, Charleston, SC, USA

PIN16	COST-EFFECTIVENESS OF POSACONAZOLE VS. FLUCONAZOLE IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE IN CANADA
	Tahami Monfared AA¹, O'Sullivan AK², Papadopoulos G3
	1Schering-Plough Canada Inc, Kirkland, QC, Canada, ²i3 Innovus, Medford, MA, USA, 3Schering-Plough Corp, Kenilworth, NJ, USA

PIN17	DECISION ANALYTIC MODEL EVALUATING THE COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS COMPLICATED SKIN AND SOFT TISSUE INFECTION
	Bounthavong M¹, Okamoto MP², Hsu D3
	1Veterans Affairs San Diego Healthcare System (VASDHS), San Diego, CA, USA, 2University of Hawaii at Hilo, College of Pharmacy, Hilo, HI, USA, 3Western University of Health Sciences, College of Pharmacy, Pomona, CA, USA

PIN18	THE IMPACT OF PEDIATRIC ADVERSE EVENTS ON THE COST-EFFECTIVENESS OF OSELTAMIVIR
	Lavelle TA¹, Uyeki TM², Prosser L1
	1Harvard University, Boston, MA, USA, ²Centers for Disease Control and Prevention, Atlanta, GA, USA

PIN19	ECONOMICAL EVALUATION OF DARUNAVIR + LOW DOSE RITONAVIR IN TREATMENT-EXPERIENCED HIV-1-INFECTED PATIENTS
	Vorobiev P¹, Avksentieva M², Lesnicheva M3
	1Moscow Medical Academy named after M.I.Sechenov, Moscow, Russia, 2Moscow Medical Academy named after M.I.Sechenov, Moscow, Moscow, Russia, 3Russian Society For Pharmacoeconomics and Outcomes Research, Moscow, Russia

PIN20	PHARMACOECONOMICS OF CHRONIC HEPATITIS B AND HEPATITIS C
	Freiberga M, Ageichenko V, Vegeris I, Babarykin D
	Medical Consulting Service Ltd, Riga, Latvia

PIN21	COST-EFFECTIVENESS OF ANIDULAFUNGIN THERAPY IN CONFIRMED CANDIDEMIA AND OTHER FORMS OF INVASIVE CANDIDIASIS IN CANADA.
	Graham CN1, Earnshaw SR1, Raymond V2
	1RTI Health Solutions, Research Triangle Park, NC, USA, 2Pfizer Canada Inc, Kirkland, QC, Canada

PIN22	PHARMACOECONOMIC ANALYSIS BASED ON GUIDELINES FOR TREATING MILD DIABETIC FOOT INFECTIONS: A DECISION TREE MODEL FOR CANADA
	Chow I, Lemos EV, Marr P, Machado M, Einarson TR
	University of Toronto, Toronto, ON, Canada

PIN23	PHARMACOECONOMIC ANALYSIS OF ANTIFUNGAL AGENTS FOR THE MANAGEMENT OF NON NEUTROPENIC PATIENTS WITH INVASIVE CANDIDIASIS AT THE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)
	Contreras-Hernandez I¹, Mould-Quevedo J², Zendejas-Villanueva J1, Guzmán-Sánchez J1, Rentería-Arellano MDC1, Davila-Loaiza G², Garduño-Espinosa J1
	1Social Security Mexican Institute, Mexico City, Mexico, 2Pfizer Mexico, Mexico City, Mexico

PIN24	COST-EFFECTIVENESS ANALYSIS OF ANIDULAFUNGIN FOR THE MANAGEMENT OF INVASIVE CANDIDIASIS IN NON-NEUTROPENIC PATIENTS IN MEXICO
	Mould-Quevedo J¹, Contreras-Hernandez I², Vega-Hernández GY1, Davila-Loaiza G1
	1Pfizer Mexico, Mexico City, Mexico, 2Social Security Mexican Institute, Mexico City, Mexico

PIN25	THE ECONOMIC IMPACT OF SINGLE-DOSE AZITHROMYCIN MICROSPHERES FORMULATION FOR THE MANAGEMENT OF ACUTE STREPTOCOCCAL PHARYNGITIS (ASP) IN MEXICO
	Arreola-Ornelas H1, Dorantes-Aguilar J1, García-Mollinedo MDL², Rosado-Buzzo AA², Mould-Quevedo J3, Davila-Loaiza G3
	1Fundación Mexicana para la Salud, Funsalud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico

PIN26	ECONOMIC EVALUATION OF SUNITINIB VS. INTERFERON-ALFA (IFN-ALFA ) IN FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) IN COLOMBIA
	Godoy JI1, Cardona AF², Alvis N3, Arango CH4, Romero M4, Spath A5, Ramirez P5, Caceres HA5, Quijano MF6
	1Hospital Militar Central, Bogotá DC, Colombia, ²Hospital Universitario San Ignacio, Bogotá D.C, Colombia, 3Universidad de Cartagena, Cartagena, Colombia, 4Synergia Consultoría y Gestión S.A, Bogotá D.C, Colombia, 5Pfizer S.A, Bogotá D.C, Colombia, 6Universidad de la Sabana, Bogotá D.C, Colombia

PIN27	ECONOMIC ANALYSIS OF MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR TREATMENT OF CANDIDAEMIA AND INVASIVE CANDIDIASIS IN THE UNITED KINGDOM
	Park G1, Sidhu M2, Van Engen AK3, Schoeman O3
	1Addenbrookes Hospital, Cambridge, UK, ²Astellas Pharma Europe Ltd, Staines, Middlesex, UK, 3Quintiles Consulting, Hoofddorp, Netherlands

PIN28	A REALISTIC-AGE-STRUCTURED, DETERMINISTIC, COMPARTMENTAL, TRANSMISSION MODEL TO ESTIMATE THE COST-EFFECTIVENESS OF VACCINATION AGAINST SEASONAL INFLUENZA
	Thompson WA¹, Eggington SG1, Tucker D²
	1IMS Health, London, UK, ²GlaxoSmithKline Biologicals, Wavre, Belgium

PIN29	COST-EFFECTIVENESS EVALUATION OF THREE HEALTH CARE DELIVERY MODELS FOR HIV POSITIVE PATIENTS IN COLOMBIA
	Burbano-Levy X¹, Valenzuela JI¹, Bryon A¹, Tono T¹, Garzon G¹, Shor-Posner G², Alvarez C³
	1Fundación Santa Fe de Bogota, Bogota, Colombia, 2University of Miami, Miami, FL, USA, 3Hospital Universitario de San Ignacio, Bogota, Colombia

PIN30	COST-MINIMIZATION ANALYSIS OF ORAL VALGANCICLOVIR VERSUS INTRAVENOUS GANCICLOVIR FOR THE PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION IN SOLID ORGAN TRANSPLANT RECIPIENTS IN BRAZIL
	David-Neto E¹, Toledo Jr ACC², Nasciben VD3, Saggia MG3
	1University of São Paulo, São Paulo, SP, Brazil, ²Faculdade de Ciências Médicas – Unifenas, Belo Horizonte, BH, Brazil, 3Roche Brazil, Sao Paulo, SP, Brazil

PIN31	TOTAL TREATMENT COST OF LINEZOLID COMPARED TO VANCOMYCIN IN MRSA INFECTIONS
	Borgman B¹, Ekman M²
	1Pfizer, Sollentuna, Sweden, ²i3 Innovus, Stockholm, Sweden

PIN32	THE CHILD AND HOUSEHOLD INFLUENZA-ILLNESS AND EMPLOYEE FUNCTION (CHIEF) STUDY – LINKING SURVEY AND CLAIMS DATA TO UNDERSTAND DISEASE IMPACT ON INDIRECT COSTS
	Rousculp MD¹, Palmer L², Johnston S², Mahadevia PJ1, Nichol KL3
	1MedImmune, Inc, Gaithersburg, MD, USA, 2Thomson Healthcare, Inc, Washington, DC, USA, 3Veterans Affairs Medical Center, Minneapolis, MN, USA

PIN33	A DYNAMIC MODEL FOR ASSESSING THE IMPACT OF EMERGING VACCINE TECHNOLOGIES ON MEASLES DISEASE BURDEN IN DEVELOPING COUNTRIES
	Bauch CT¹, Szusz E1, Bresnahan B², Hazlet TK², Kadiyala S², Veenstra DL², Garrison L²
	1University of Guelph, Guelph, ON, Canada, 2University of Washington, Seattle, WA, USA

PIN34	HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH CHRONIC HEPATITIS C IN A MANAGED CARE POPULATION
	Mitra D¹, Davis KL1, Medjedovic J², Beam C3, Rustgi V4
	1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, Switzerland, 3Human Genome Sciences, Inc, Rockville, MD, USA, 4Georgetown University Medical Center, Fairfax, VA, USA

PIN35	RESOURCE UTILIZATION IN UNITED KINGDOM DIAGNOSED HCV PATIENTS
	Zhang H, Hill K, Budd D
	Johnson & Johnson, Raritan, NJ, USA

PIN36	BASELINE CHARACTERISTICS ASSOCIATED WITH HOSPITAL LENGTH OF STAY (LOS) FOR PATIENTS WITH STAPHYLOCOCCUS AUREUS SKIN INFECTIONS IN THE 1996-2005 NATIONAL HOSPITAL DISCHARGE SURVEY (NHDS)
	Miller ML, Frei CR
	University of Texas at Austin and University of Texas Health Sci. Ctr. at San Antonio, San Antonio, TX, USA

PIN37	AN EXAMINATION OF THE CORRELATION BETWEEN QUALITY OF PATIENT CARE AND PATIENT RACE OR SOCIAL CLASS IN INPATIENT APPENDICITIS CASES
	Cerrito PB, Talbot S
	University of Louisville, Louisville, KY, USA

INFECTION Patient-Reported Outcomes
PIN38	RANDOMIZED CONTROLLED TRIAL OF TELEPHONE, EMAIL AND TEXT MESSAGING REMINDERS ON PATIENT COMPLIANCE WITH ANTIBIOTIC REGIMEN
	Yang Y¹, Sangasubana N², Bentley SI1, Thumula V1, Mendonca C1
	1University of Mississippi, University, MS, USA, 2Nova Southeastern University, Fort Lauderdale, FL, USA

PIN39	ROLE OF DRUG DISTRIBUTION STRATEGIES TO IMPROVE HEALTH OUTCOME IN HIGH RISK PATIENTS
	Wattal R, Yeh R, Sansgiry S
	University of Houston, Houston, TX, USA

PIN40	ASSESSMENT OF THE CROSS-CULTURAL VALIDITY OF AN HIV SYMPTOM DISTRESS MODULE IN AN INTERNATIONAL HIV CLINICAL TRIAL
	Regnault A¹, Marfatia S², Louie M², Viala M1
	1Mapi Values France, Lyon, France, 2Pfizer Inc, New York, NY, USA

PIN41	COMPLEMENTARY AND ALTERNATIVE MEDICATION USE AND ADVERSE EVENTS IN HIV-INFECTED PATIENTS
	Ajugo E1, Yeh R1, Wattal R¹, GatheJr J², Sansgiry S1
	1University of Houston, Houston, TX, USA, 2Therapeutic Concepts, Houston, TX, USA

PIN42	DESIGNING AND TESTING A HIV-PATIENT SATISFACTION SURVEY FOR A COMPARITIVE ANALYSIS OF MAIL-ORDER PHARMACY VS. COMMUNITY PHARMACY SERVICES
	Ramasamy A, Pinto SL, Sahloff EG
	University of Toledo, Toledo, OH, USA

INFECTION Health Care Use & Policy Studies
PIN43	NATURAL HISTORY OF CHRONIC HCV INFECTION OBTAINED THROUGH INJECTION DRUG USE: A BAYESIAN META-ANALYSIS
	John-Baptiste A¹, Krahn MD², Heathcote J², Tomlinson G3
	1Toronto General Hospital, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada

PIN44	ANTIBIOTIC PRESCRIBING IN THE HOSPITAL EMERGENCY DEPARTMENT
	Cerrito PB¹, Cerrito JC²
	1University of Louisville, Louisville, KY, USA, 2Kroger Pharmacy, Louisville, KY, USA

PIN45	COMPREHENSIVE EDUCATIONAL APPROACH HOW TO INFLUENCE PRESCRIPTION HABITS AND ANTIBIOTIC RESISTANCE IN AMBULATORY PRACTICE
	Hupkova H1, Foltán V2, Hroncova D3, Gezo M1
	1General Health Insurance Fund, Bratislava, Slovak Republic, ²Comenius University, Bratislava, Slovak Republic, 3GSK, Bratislava, Slovak Republic

PIN46	COUNTRY ASSESSMENT TO DETERMINE FACTORS INFLUENCING THE COST, AVAILABILITY AND DISTRIBUTION OF ACYCLOVIR IN EIGHT SUB-SAHARAN AFRICAN COUNTRIES
	Waweru CW
	University of Washington, Seattle, WA, USA

PIN47	INPATIENT COSTS AND OUTCOMES ASSOCIATED WITH CHRONIC HEPATITIS C RELATED COMPLICATIONS IN THE UNITED STATES
	Mitra D, Candrilli SD, Davis KL, Bapat B
	RTI Health Solutions, Research Triangle Park, NC, USA

PIN48	TRENDS FOR NOSOCOMIAL SOFT TISSUE INFECTIONS, STAPHLOCOCCOUS AUREUS INFECTIONS, AND MRSA IN US HOSPITALS: 1998–2004
	Dickson M¹, Kotchmar G², Roberts D3
	1University of South Carolina, College of Pharmacy, Columbia, SC, USA, 2University of South Carolina, Columbia, SC, USA, 3South Carolina Department of Health and Environmental Control, Columbia, SC, USA

PIN49	SPREAD PATTERN FORMATION OF H5N1-AVIAN INFLUENZA AND ITS IMPLICATIONS FOR CONTROL STRATEGIES
	Duvvuri VRSK¹, Liu R², Wu J1
	1York University, Toronto, ON, Canada, 2Purdue University, West Lafayette, IN, USA

PIN50	INITIAL THERAPIES FOR ACUTE OTITIS EXTERNA IN THE LOUISIANA MEDICAID POPULATION
	Parmar J, Jain G, Baggarly S, Jenkins T, Lawrence L
	University of Louisiana at Monroe, Monroe, LA, USA

PIN51	A PICTURE OF DEMOGRAPHIC DISPARITIES IN THE RECEIPT OF ANTIRETROVIRAL THERAPY AMONG HIV PATIENTS IN THE 2000-2005 NATIONAL AMBULATORY MEDICAL CARE SURVEYS (NAMCS)
	Oramasionwu CU, Ryan L, Frei CR
	University of Texas at Austin and University of Texas Health Sci. Ctr. at San Antonio, San Antonio, TX, USA

PIN52	PRESCRIBING TRENDS IN ANTIVIRAL PRESCRIPTIONS AMONG PATIENTS WITH INFLUENZA IN THE UNTED STATES FROM 1999-2005
	Bonthapally V¹, Baggarly S1, Sabyasachi G²
	1University of Louisiana at Monroe, Monroe, LA, USA, 2Oklahoma University Health Center, OKLAHOMA, OK, USA

MENTAL HEALTH CLINICAL OUTCOMES STUDIES

PMH1	ESTIMATING THE MAGNITUDE OF ORAL ANTIPSYCHOTIC DRUG-DRUG INTERACTIONS
	Howe A¹, Pesa J², Kozma C3
	1Ortho-McNeil Janssen Scientific Affairs, LLC, Alpharetta, GA, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Superior, CO, USA, 3Independent Consultant, West Columbia, SC, USA

PMH2	BENCHMARKING SCHIZOPHRENIA WITH A FOCUS ON PHARMACOTHERAPY AND METABOLIC SYNDROME
	Prescott J
	The MCM Group, Marlton, NJ, USA

PMH3	STATISTICAL ANALYSIS OF SIGNIFICANT VARIABLES IN DEALING WITH DRUG ABUSE INPATIENTS
	Cerrito PB, Harrison KB
	University of Louisville, Louisville, KY, USA

PMH4	ATYPICAL ANTIPSYCHOTIC MEDICATIONS IN THE TREATMENT OF SCHIZOPHRENIA: A BAYESIAN META-ANALYSIS OF DIRECT AND INDIRECT COMPARISONS
	Mahmood MH, Malone DC
	University of Arizona, College of Pharmacy, Tucson, AZ, USA

PMH5	REHOSPITALIZATION AFTER DISCONTINUATION OF PALIPERIDONE ER IN PATIENTS WITH SCHIZOPHRENIA
	Wu JH1, Mao L1, Pesa J², Lee SP3
	1Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Superior, CO, USA, 3Jefferson Medical College, Philadelphia, PA, USA

PMH6	OPTIMAL THRESHOLDS OF EARLY NON-RESPONSE TO ATYPICAL ANTIPSYCHOTICS: APPLICATION OF SIGNAL DETECTION ANALYSIS
	Ascher-Svanum H, Chen L, Stauffer V, Kinon BJ, Tomori O, Kollack-Walker S
	Eli Lilly and Company, Indianapolis, IN, USA

PMH7	CLINICAL AND FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG ACTING INJECTION: INTERIM RESULTS FROM OBSERVATIONAL STUDIES CONDUCTED IN AUSTRALIA, BELGIUM AND THE UNITED STATES.
	Emmerson B1, Peuskens J², Vallow S3, Povey M4, Lam A5, Zhao Z6
	1Royal Brisbane and Women's Hospital, Herston, Queensland, Australia, 2Universitair Psychiatrisch Centrum, KUL Leuven, Leuven, Belgium, 3JJPS, Raritan, NJ, USA, 4SGS Biopharma, Wavre, Belgium, 5JJPS, Toronto, ON, Canada, 6Johnson and Johnson Pharmaceutical Services, Raritan, NJ, USA

PMH8	TREATMENT DURATION FOLLOWING INITIATION ON ATYPICAL ANTIPSYCHOTICS AMONG SCHIZOPHRENIA PATIENTS WITH VERSUS WITHOUT A METABOLIC SYNDROME
	Shi L¹, Ascher-Svanum H², Chiang YJ1, Fonseca V1, Winstead D1
	1Tulane University, New Orleans, LA, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PMH9	RETENTION RATES FOR ORAL AND DEPOT ANTIPSYCHOTIC MEDICATIONS OVER ONE YEAR IN ONTARIO, CANADA
	Glass JR, Luong D
	Janssen-Ortho Inc, Toronto, ON, Canada

PMH10	TREATMENT PATTERNS PRIOR TO INITIATING DEPOT TYPICAL ANTIPSYCHOTICS FOR NON-ADHERENT SCHIZOPHRENIA PATIENTS
	Peng X¹, Ascher-Svanum H1, Faries D1, Montgomery W²
	1Eli Lilly and Company, Indianapolis, IN, USA, ²Eli Lilly and Company, Sydney, NSW, Australia

PMH11	ASSESSING THE REPORTING AND SCIENTIFIC QUALITY OF META-ANALYTIC RESEARCH SYNTHESISING RANDOMIZED CONTROLLED TRIALS FOR ANXIETY DISORDER TREATMENTS
	Bereza BG, Machado M, Einarson TR
	University of Toronto, Toronto, ON, Canada

PMH12	TREATMENT OUTCOMES OF RISPERIDONE LONG ACTING INJECTION (RLAI) IN SCHIZOPHRENIA: 18-MONTH RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN CZECH REPUBLIC AND SLOVAKIA
	Tuma I1, Pecenak J², Povey M3, Lam A4, Zhao Z5
	1FNSP Hradec Kralove, Hradec Kralove, Czech Republic, ²FNSP Bratislava, Bratislava, Slovak Republic, 3SGS Biopharma, Wavre, Belgium, 4JJPS, Toronto, ON, Canada, 5Johnson and Johnson Pharmaceutical Services, Raritan, NJ, USA

PMH13	WITHDRAWN

PMH14	DIFFERENTIAL EFFECTS OF OLANZAPINE AND CLOZAPINE ON TYPE II DIABETES: FINDINGS FROM A CLAIMS DATABASE
	Donga PZ, Pandey GS, Chen H
	University of Houston, Houston, TX, USA

PMH15	ANALYSIS OF POTENTIAL DRUG-DRUG INTERACTION PAIRS ASSOCIATED WITH ANTIPSYCHOTICS AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER
	Jing Y¹, Guo JJ1, Patel NC², Kelton CM1, Fan H3, Keck P1
	1University of Cincinnati, Cincinnati, OH, USA, 2University of Georgia, Augusta, GA, USA, 3Covance Inc, Sun Prairie, WI, USA

PMH16	METABOLIC SAFETY AND TOLERABILITY OF ZIPRASIDONE VS. OLANZAPINE IN SCHIZOPHRENIA PATIENTS: SYSTEMATIC REVIEW AND META-ANALYSIS
	Campbell RS1, Xiong Y1, Erensen JG², Shah NR3, Bernal MC1, Miller RM1, Sanders KN², Masters ET2, Harnett J², Kremer CM²
	1Cerner LifeSciences, Beverly Hills, CA, USA, 2Pfizer Inc, New York, NY, USA, 3New York University School of Medicine, New York, NY, USA

PMH17	METABOLIC MONITORING AMONG SCHIZOPHRENIA PATIENTS INITIATED ON ATYPICAL ANTIPSYCHOTICS IN THE VETERAN HEALTH ADMINISTRATION
	Shi L¹, Ascher-Svanum H², Chiang YJ1, Fonseca V1, Winstead D1
	1Tulane University, New Orleans, LA, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PMH18	RISK OF NEUROLEPTIC MALIGNANT SYNDROME ASSOCIATED WITH ANTIPSYCHOTICS USE IN PATIENTS WITH BIPOLAR DISORDER: A RETROSPECTIVE POPULATION-BASED CASE-CONTROL STUDY
	Chen Y¹, Guo JJ1, Patel NC², Steinbuch M3, Lin XD1, Buncher C4
	1University of Cincinnati, Cincinnati, OH, USA, 2University of Georgia, Augusta, GA, USA, 3P&G Pharmaceuticals, Inc, Mason, OH, USA, 4University of Cincinnati Medical Center, Cincinnati, OH, USA

MENTAL HEALTH Cost Studies
PMH19	MONOTHERAPY WITH ATYPICAL ANTIPSYCHOTICS FOR SCHIZOPHRENIA: A CLINICAL REVIEW AND ECONOMIC EVALUATION OF FIRST TWELVE MONTHS OF TREATMENT
	Farahati F¹, Boucher M², Williams R3, Moulton K², Herrmann N4, Normandin S²
	1North American HERG, Toronto, ON, Canada, ²CADTH, Ottawa, ON, Canada, 3University of British Columbia, University of Victoria, Schizophrenia Service, Victoria, B.C, BC, Canada, 4University of Toronto, Toronto, ON, Canada

PMH20	A COST-BENEFIT ANALYSIS OF HIGHER MEDICATION COPAYMENTS IN VETERANS WITH SCHIZOPHRENIA
	Zeber JE¹, Copeland LA1, Valenstein M², Miller AL3
	1Veterans Affairs HSRD / UTHSCSA, San Antonio, TX, USA, 2Veterans Affairs HSRD / University of Michigan, Ann Arbor, MI, USA, 3UTHSCSA, San Antonio, TX, USA

PMH21	PHARMACY COST IMPACT OF GUIDELINE-RECOMMENDED DOSING OF SECOND GERNERATION ANTIPSYCHOTICS IN SCHIZOPHRENIA
	Chen CC¹, Kim E1, Yu Y², Kan HJ², Whitehead R3
	1Bristol-Myers Squibb, Plainsboro, NJ, USA, ²Bristol-Myers Squibb, Wallingford, CT, USA, 3Otsuka America Pharmaceutical Inc, Rockville, MD, USA

PMH22	ECONOMIC ASSESSMENT OF THREE COMMONLY USED ANTIPSYCHOTIC AGENTS IN THE PUBLIC SECTOR OF HONG KONG USING A DECISION ANALYTIC MODEL
	Lee KK, Lee VWY
	The Chinese University of Hong Kong, Shatin, Hong Kong

PMH23	A COMPARISION OF HEALTH CARE UTILIZATION AND COST OF CHILDREN AND ADOLESCENTS WITH BIPOLAR DISORDER TREATED WITH ATYPICAL ANTIPSYCHOTIC MONOTHERAPY VERSUS MOOD STABILIZER MONOTHERAPY
	Jing Y¹, Guo JJ1, Patel NC², Heaton PC1, Li H3, Kelton CM1
	1University of Cincinnati, Cincinnati, OH, USA, 2University of Georgia, Augusta, GA, USA, 3Bristol-Myers Squibb Company, Singapore, Singapore

PMH24	INITIATING TREATMENT ON GENERIC ANTIDEPRESSANTS MAY NOT SAVE HEALTH CARE COSTS
	Esposito D¹, Wahl P², Daniel G², Stoto MA3, Erder MH4, Croghan TW5
	1Mathematica Policy Research, Inc, Princeton, NJ, USA, ²HealthCore, Inc, Wilmington, DE, USA, 3Georgetown University School of Nursing and Health Studies, Washington, DC, USA, 4Forest Research Institute, Jersey City, NJ, USA, 5Mathematica Policy Research, Washington, DC, USA

PMH25	HEALTH CARE USE AND COSTS OF PATIENTS WITH “PURE OBSESSIVE-COMPULSIVE DISORDER” VERSUS “PURE DEPRESSION”: 9-YEAR (1997-2006), LARGE-SCALE, RETROSPECTIVE CLAIMS ANALYSIS OF FLORIDA MEDICAID ADULT ENROLLEES
	Hankin C¹, Knispel J², Dunn JD3, Levin A4, Culpepper L5, Dougherty D6, Koran L7, Hollander E8, Sheehan D9, Black D10, Bronstone A1, Wang Z1
	1BioMedEcon, Moss Beach, CA, USA, ²Humana, Singer Island, FL, USA, 3SelectHealth Plans, Salt Lake City, UT, USA, 4Health Plus, Bronx, NY, USA, 5Boston University Medical Center, Boston, MA, USA, 6Massachusetts General Hospital, Charlestown, MA, USA, 7Stanford University School of Medicine, Stanford, CA, USA, 8Mount Sinai School of Medicine, New York, NY, USA, 9University of South Florida College of Medicine, Tampa, FL, USA, 10University of Iowa, Iowa City, IA, USA

PMH26	IMPROVED WORK PRODUCTIVITY IN THE UNITED STATES (US) FOR PATIENTS TREATED WITH ESCITALOPRAM COMPARED TO DULOXETINE
	François C1, Danchenko N¹, Despiégel N1, Erder MH²
	1Lundbeck SAS, Paris, France, ²Forest Research Institute, Jersey City, NJ, USA

PMH27	COST-EFFECTIVENESS OF A MINIMAL INTERVENTION STRATEGY FOR STRESS-RELATED SICK LEAVE IN GENERAL PRACTICE: RESULTS OF AN ECONOMIC EVALUATION ALONGSIDE A PRAGMATIC RANDOMIZED CONTROLLED TRIAL
	Uegaki K¹, Bakker IM², De Bruijne MC1, Van der Beek AJ1, Terluin B1, Van Marwijk HW1, Heymans MW1, Stalman WA3, Van Mechelen W1
	1EMGO Institute-VU University Medical Center, Amsterdam, Netherlands, 2Wageningen University, Wageningen, Netherlands, 3VU University Medical Center, Amsterdam, Netherlands

PMH28	COST-EFFECTIVENESS OF ONCE-DAILY STIMULANT, NON-STIMULANT & COMBINED STIMULANT/BEHAVIORAL THERAPY INTERVENTIONS IN THE TREATMENT OF ADHD IN CHILDREN
	Ganapathy V, Hay JW
	University of Southern California, Los Angeles, CA, USA

PMH29	WITHDRAWN

PMH30	COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION WITH LITHIUM OR DIVALPROEX: IN THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
	Woodward TC1, Lazarus A², Quon P1, Tafesse E2, Fleurence RL3
	1United BioSource Corporation, Bethesda, MD, USA, ²AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 3United BioSource Corporation Health Analytics Group, Bethesda, MD, USA

PMH31	A PHARMACOECONOMIC ANALYSIS OF SCHIZOPHRENIC PATIENTS SWITCHING FROM BRANDED TO GENERIC RISPERIDONE INVOLVING A POSSIBLE COMPLIANCE LOSS
	Treur MJ¹, Heeg B1, Möller HJ², Schmeding A3, Van Hout BA4
	1Pharmerit Europe, Rotterdam, Zuid-Holland, Netherlands, 2Psychiatrische Klinik der Ludwig-Maximilians-Universität, München, Germany, 3Janssen-Cilag GmbH, Neuss, Germany, 4Pharmerit Europe, Rotterdam, Netherlands

PMH32	ACAMPROSATE IN TREATMENT OF ALCOHOL DEPENDENCE – ECONOMIC BENEFITS REVISITED
	Erder MH¹, Weycker D², Oster G²
	1Forest Research Institute, Jersey City, NJ, USA, 2Policy Analysis Inc. (PAI), Brookline, MA, USA

PMH33	COST-EFFECTIVENESS OF ARIPIPRAZOLE FOR THE MANAGEMENT OF SCHIZOPHRENIA IN THE UNITED KINGDOM
	Davies A1, Vardeva K², Loze JY3, L'Italien GJ4, Sennfalt K5, Pugner K6, van Baardewijk M6
	1Oxford Outcomes (UK), Oxford, England, ²Bristol-Myers Squibb, Uxbridge, UK, 3Otsuka Pharmaceutical France, Paris, France, 4Bristol-Myers Squibb, Wallingford, CT, USA, 5Bristol-Myers Squibb, Bromma, Sweden, 6Bristol-Myers Squibb, Braine l'Alleud, Belgium

PMH34	TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): ESTIMATING THE MAXIMUM ALLOWABLE COST OF PSYCHOSOCIAL INTERVENTIONS IN THE UNITED STATES, GERMANY, THE NETHERLANDS, SWEDEN, AND THE UNITED KINGDOM
	Schlander M¹, Schwarz O1, Hakkaart-van Roijen L², Jensen PS3, Persson U4, Santosh PJ5, Trott GE6
	1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, ²Erasmus MC, Rotterdam, Netherlands, 3Columbia University, New York, NY, USA, 4The Swedish Institute for Health Economics, IHE, Lund, Sweden, 5Institute of Child Health - Great Ormond Street Hospital, London, UK, 6University of Wuerzburg, Aschaffenburg, Germany

PMH35	COST-EFFECTIVENESS OF ORALLY DISSOLVING OLANZAPINE TABLETS IN THE TREATMENT OF SCHIZOPHRENIA IN THE USA
	Ascher-Svanum H1, Furiak NM², Klein RW², Smolen LJ², Watson PR¹, Lawson AH1
	1Eli Lilly and Company, Indianapolis, IN, USA, 2Medical Decision Modeling, Inc, Indianapolis, IN, USA

PMH36	WITHDRAWN

PMH37	UNITED KINGDOM COST-CONSEQUENCE ANALYSIS OF ARIPIPRAZOLE IN SCHIZOPHRENIA: DIABETES AND CORONARY HEART DISEASE RISK PROJECTIONS (STAR STUDY)
	Barnett AH1, Millar H², Loze JY3, L'Italien GJ4, van Baardewijk M5, Knapp M6
	1University of Birmingham and Heart of England NHS Foundation Trust, Birmingham, West Midlands, UK, 2Tayside Primary Care Division, Dundee, UK, 3Otsuka Pharmaceutical France, Paris, France, 4Bristol-Myers Squibb, Wallingford, CT, USA, 5Bristol-Myers Squibb, Braine l'Alleud, Belgium, 6London School of Economics, London, UK

PMH38	GENERALIZED ANXIETY DISORDER: A COMPREHENSIVE LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN NORTH AMERICA
	Wyrwich K¹, Mattera MS¹, Svedsater H2, Locklear JC3, Revicki D1, Sheehan D4
	¹United BioSource Corporation, Bethesda, MD, USA, ²AstraZeneca Pharmaceuticals, Sodertalje, Sweden, ³AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, ⁴University of South Florida College of Medicine, Tampa, FL, USA

PMH39	THE PREVALENCE AND COSTS OF METABOLIC CONDITIONS AMONG PATIENTS WITH BIPOLAR DISORDERS AS COMPARED TO MATCHED CONTROLS
	Mark TL¹, Centorrino F², Talamo A², Oh K1, Chang J3
	1Thomson Healthcare, Washington, DC, USA, ²Harvard Medical School/McLean Hospital, Belmont, MA, USA, 3Bayer HealthCare Pharmaceuticals, Pine Brook, NJ, USA

PMH40	TREATMENT COST AND COMORBIDITIES ASSOCIATED WITH OBESITY AMONG MEDICAID PATIENTS WITH BIPOLAR DISORDER
	Guo JJ¹, Kelton CM1, Jing Y1, Patel NC²
	1University of Cincinnati, Cincinnati, OH, USA, 2University of Georgia, Augusta, GA, USA

PMH41	COST UTILITY OF EEG BIOMARKERS FOR PERSONALIZED TREATMENT OF MAJOR DEPRESSION
	Simpson KN¹, Nahas Z1, Leuchter AF², Siegel A3, Greenwald S3
	1Medical University of South Carolina, Charleston, SC, USA, 2UCLA, Los Angeles, CA, USA, 3Aspect Medical Systems, Norwood, MA, USA

PMH42	IMPACT OF RISPERIDONE LONG-ACTING INJECTION VERSUS ORAL ANTIPSYCHOTIC TREATMENTS ON HOSPITALIZATION IN SCHIZOPHRENIA
	Olivares JM1, Rodriguez-Morales A², Diels JK3, Povey M4, Lam A5, Jacobs A3, Zhao Z6
	1Servicio de Psiquiatria Hospital, Vigo, Spain, 2Janssen cilag, Madrid, Spain, 3Janssen Pharmaceutica, Beerse, Belgium, 4SGS Biopharma, Wavre, Belgium, 5JJPS, Toronto, ON, Canada, 6Johnson and Johnson Pharmaceutical Services, Raritan, NJ, USA

PMH43	MENTAL HEALTH CARE RESOURCE USE BEFORE AND AFTER INITIATION OF PALIPERIDONE ER IN PATIENTS WITH SCHIZOPHRENIA
	Wu JH1, Mao L1, Pesa J², Lee SP3
	1Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Superior, CO, USA, 3Jefferson Medical College, Philadelphia, PA, USA

PMH44	HEALTH CARE RESOURCE UTILIZATION AND COSTS COMPARISON FOR MDD PATIENTS ON 10MG ESCITALOPRAM WHO INCREASED TO 20MG DOSE VS. THOSE WHO WERE SWITCHED TO SNRI
	Wu E¹, Yu AP1, Buessing M1, Ben-Hamadi R1, Tang J1, Seale J1, Erder MH², Bose A²
	1Analysis Group, Inc, Boston, MA, USA, ²Forest Research Institute, Jersey City, NJ, USA

PMH45	COST OF PSYCHIATRIC HOSPITALIZATIONS IN THE UNITED STATES IN 2006
	Stensland M, Liu L
	Eli Lilly and Company, Indianapolis, IN, USA

MENTAL HEALTH Patient-Reported Outcomes
PMH46	PREDICTORS OF MEDICATION ADHERENCE AMONG SCHIZOPHRENIA PATIENTS TREATED WITH CONVENTIONAL AND ATYPICAL ANTIPSYCHOTICS IN A LARGE STATE MEDICAID PROGRAM
	Lee SP¹, Lang K², Jackel J², Crivera C3, Dirani RG4, Menzin J5
	1Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, ²Boston Health Economics, Inc, Waltham, MA, USA, 3Ortho-McNeil Janssen Scientific Affairs, L.L.C, Titusville, NJ, USA, 4Ortho-McNeil Janssen Scientific Affairs, Titusville, NJ, USA, 5Boston Health Economics, Waltham, MA, USA

PMH47	THE RELATIONSHIP BETWEEN THE ANTIPSYCHOTIC MEDICATION ADHERENCE AND PATIENT OUTCOMES AMONG BIPOLAR DISORDER PATIENTS
	Lage MJ1, Hassan M2
	1HealthMetrics Outcomes Research, LLC, Groton, CT, USA, ²AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

PMH48	BETTER PERSISTENCE ON TREATMENT WITH ESCITALOPRAM COMPARED WITH CITALOPRAM
	Ereshefsky L¹, Despiégel N², Maman K², François C², Saragoussi D²
	1California Clinical Trials, Glendale, CA, USA, 2Lundbeck SAS, Paris, France

PMH49	EARLY DISCONTINUATION ON TREATMENT AND ITS CONSEQUENCES IN PATIENTS TREATED WITH VENLAFAXINE OR ESCITALOPRAM
	Ereshefsky L¹, Cournau S², Hansen K², Milea D², Verpillat P²
	1California Clinical Trials, Glendale, CA, USA, 2Lundbeck SAS, Paris, France

PMH50	MEDICATION ADHERENCE, ETHNICITY, AND THE INFLUENCE OF MULTIPLE PSYCHOSOCIAL AND FINANCIAL BARRIERS IN VETERANS WITH BIPOLAR DISORDER
	Zeber JE¹, Copeland LA1, Miller AL², Valenstein M3, McCarthy JF3, Zivin K3, Kilbourne AM3
	1Veterans Affairs HSRD / UTHSCSA, San Antonio, TX, USA, 2UTHSCSA, San Antonio, TX, USA, 3Veterans Affairs HSRD / University of Michigan, Ann Arbor, MI, USA

PMH51	A NEW MEASURE OF ADHERENCE – THE DAILY POSSESSION RATIO (DPR): COMPARISONS WITH THE MEDICATION POSSESSION RATIO (MPR) IN THE PRESENCE OF MEDICATION SWITCHING AND THERAPEUTIC DUPLICATION
	Martin BC¹, Wiley-Exley E², Richards S², Domino ME², Carey TS², Sleath B²
	1University of Arkansas for Medical Sciences, Little Rock, AR, USA, 2University of North Carolina, Chapel Hill, NC, USA

PMH52	COSTS OF NON-COMPLIANCE WITH ANTIPSYCHOTIC MEDICATIONS AMONG PATIENTS WITH SCHIZOPHRENIA
	Salas M¹, Zuluaga A1, Hughes D², Lebmeier M3, Vardeva K4, Pisu M1, Shinogle J5
	1University of Alabama at Birmingham, Birmingham, AL, USA, 2University of Wales, Bangor, Bangor, UK, 3University of Sheffield, Sheffield, -, UK, 4GlaxoSmithKline, Greenford, Middlesex, UK, 5RTI International, Washington, DC, USA

PMH53	IMPACT OF ALTERNATIVE TREATMENTS ON DURATION OF DRUG THERAPY BY PATIENTS WITH BIPOLAR DISORDER
	Ganapathy V¹, McCombs JS², Stafkey-Mailey D1, Kim E3, Pikalov A4
	1University of Southern California School of Pharmacy, Los Angeles, CA, USA, 2University of Southern California, Los Angeles, CA, USA, 3Bristol-Myers Squibb, Plainsboro, NJ, USA, 4Otsuka America Pharmaceuticals, Rockville, MD, USA

PMH54	IMPACT OF ALTERNATIVE TREATMENTS ON DURATION OF DRUG THERAPY BY PATIENTS WITH SCHIZOPHRENIA
	Zolfaghari S¹, McCombs JS², Stafkey-Mailey D3, Ganapathy V3, Kim E4, Pikalov A5
	1University of Southern California, School of Pharmacy, Los Angeles, CA, USA, 2University of Southern California, Los Angeles, CA, USA, 3University of Southern California School of Pharmacy, Los Angeles, CA, USA, 4Bristol-Myers Squibb, Plainsboro, NJ, USA, 5Otsuka America Pharmaceuticals, Rockville, MD, USA

PMH55	MEDICATION COMPLIANCE IN THOSE WITH SCHIZOPHRENIA RECEIVING PSYCHIATRIC SERVICES FROM A VETERANS HOSPITAL IN TAIWAN
	Cheng JS¹, Huang WF², Lai IC3
	1National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan, 2National Yang-Ming University, Taipei, Taiwan, 3Yu-Li Veterans Hospital, Yu-Li, Hualien, Taiwan

PMH56	THE IMPACT OF DULOXETINE, VENLAFAXINE AND ESCITALOPRAM USE AND PRESCRIPTION COPAYS ON MEDICATION PERSISTENCE, HEDIS MEASURES AND EXPENDITURES
	Nair K¹, Van Den Bos J², Valuck RJ3, Draaghtel K²
	1University of Colorado at Denver, Aurora, CO, USA, 2Milliman, Inc, Denver, CO, USA, 3University of Colorado, Denver, CO, USA

PMH57	MEDICATION PERSISTENCE AND ASSOCIATED HEALTH CARE COSTS IN AN OLDER POPULATION WITH DEMENTIA: A LONGITUDINAL COHORT STUDY
	Balkrishnan R1, Kong MC2, Bonza S1, Anderson RT3
	1The Ohio State University, Columbus, OH, USA, 2The Ohio State University College of Pharmacy, Columbus, OH, USA, 3Wake Forest University School of Medicine, Winston Salem, NC, USA

PMH58	IMPROVEMENT IN PERSONAL AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS TREATED WITH RISPERIDONE LONG ACTING INJECTION): 6-MONTH RESULTS FROM E-STAR
	Pecenak J1, Tuma I², De groot-stam E3, Eriksson L4, Bork B5, Ligate L6, Povey M7, Lam A8, Trakas K9, Zhao Z10
	1FNSP Bratislava, Bratislava, Slovak Republic, ²FNSP Hradec Kralove, Hradec Kralove, Czech Republic, 33Gelderse Roos/RIAGG, Veenendaal, Veenendaal, Netherlands, 46SU/Östra RPV, Hisings-Backa, Sweden, 5DP Tønder, Tønder, Denmark, 6Cambridge Memorial Hospital, Cambridge, ON, Canada, 7SGS Biopharma, Wavre, Belgium, 8JJPS, Toronto, ON, Canada, 9Johnson & Johnson, Toronto, ON, Canada, 10Johnson & Johnson Pharmaceutical Services, Raritan, NJ, USA

PMH59	HEALTH RELATED QUALITY OF LIFE IN PATIENTS TREATED WITH ANTIPSYCHOTIC DRUGS: RESULTS AT BASELINE FROM THE COMETA STUDY
	Scalone L¹, Mantovani LG², Ferrarini L3, Mencacci C4, Pirfo E5, Bernareggi M6, Giustra MG6, Berto P7, Sturkenboom MC8
	1Centre of Pharmacoeconomics, Milan, Italy, 2University of Naples, Federico II, Naples, Italy, 3Mental Health Department ASL 3, Genova, NA, Italy, 4Mental Health Department, Milan, NA, Italy, 5Mental Health Department G. Maccacaro, Torino, NA, Italy, 6Janssen-Cilag SpA, Cologno Monzese, Milan, NA, Italy, 7PBE Consulting, Verona, Italy, 8Erasmus University Medical Center, Soest, Netherlands

PMH60	HEALTH STATUS AND WORK-RELATED OUTCOMES OF PATIENTS WITH ANXIETY DISORDERS AND DEPRESSION
	Erickson S, Guthrie S, Abelson J
	University of Michigan, Ann Arbor, MI, USA

PMH61	PATIENT PREFERENCES IN THE THERAPY OF ADHD - A DISCRETE CHOICE EXPERIMENT
	Mühlbacher AC¹, Rudolph I², Lincke HJ1, Nübling M1
	1Gesellschaft für empirische Beratung mbH, D- 79211 Denzlingen, Germany, 2Janssen Cilag GmbH, Neuss/Germany, D-41470 Neuss, Germany

PMH62	ASSESSING THE VALIDITY OF DERIVING CLINICAL DEMENTIA RATING (CDR) GLOBAL SCORES FROM INDEPENDENTLY OBTAINED FUNCTIONAL RATING SCALE (FRS) SCORES IN VASCULAR DEMENTIA AND MIXED VASCULAR DEMENTIA PATIENTS
	Lanctôt KL1, Herrmann N1, Hsiung GYR², Masoud ST¹
	1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2University of British Columbia, Vancouver, BC, Canada

PMH63	PATIENT REPORTED MEASURES AS QUALITY ASSURANCE TOOLS IN CNS CLINICAL TRIALS
	Daniel DG¹, Friedmann B², Butler A3
	1United BioSource Corporation, McLean, VA, USA, 2UnitedBiosource Corporation, Wayne, PA, USA, 3United BioSource Corporation, Wayne, PA, USA

PMH64	MAJOR DEPRESSIVE DISORDER: A COMPREHENSIVE LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN NORTH AMERICA
	Van Hanswijck de Jonge P1, Stafford M1, Hearn S1, Tschaut N1, Svedsater H², Locklear JC3, Revicki D4, Brown R¹, Trivedi M5
	1United BioSource Corporation, London, UK, ²AstraZeneca Pharmaceuticals, Sodertalje, Sweden, 33AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 4United BioSource Corporation, Bethesda, MD, USA, 5Texas Southwestern Medical School, Dallas, TX, USA

MENTAL HEALTH Health Care Use & Policy Studies
PMH65	EFFECT OF PRIOR AUTHORIZATION ON ANTIPSYCHOTIC DRUG USE IN LONG-TERM CARE: POPULATION-BASED NATURAL EXPERIMENT
	Paterson JM¹, Bronskill S1, Sutherland J², Warren L3, Sykora K1, Bassett K², Anderson GM1, Rochon PA1
	1Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 2Therapeutics Initiative, Vancouver, BC, Canada, 3British Columbia Ministry Health, Victoria, BC, Canada

PMH66	ETHNICITY AND THE IMPACT OF HIGHER MEDICATION COPAYMENTS AMONG VETERANS WITH SCHIZOPHRENIA
	Zeber JE¹, Copeland LA1, Miller AL², Kilbourne AM3, Velligan DI², Mortensen EM²
	1Veterans Affairs HSRD / UTHSCSA, San Antonio, TX, USA, 2UTHSCSA, San Antonio, TX, USA, 3Veterans Affairs HSRD / University of Michigan, Ann Arbor, MI, USA

PMH67	CLINICAL CHARACTERISTICS AMONG ANTIDEPRESSANT INITIATORS
	Able S, Robinson RL, Ye W, Swindle R
	Eli Lilly and Company, Indianapolis, IN, USA

PMH68	CHANGES OVER TIME IN PATIENT CHARACTERISTICS FOLLOWING THE INTRODUCTION OF DULOXETINE: A 24 MONTHS STUDY
	Able S, Watson PR, Swindle R
	Eli Lilly and Company, Indianapolis, IN, USA

PMH69	WITHDRAWN

PMH70	AN INVESTIGATION OF EVIDENCE-BASED USE OF ATYPICAL ANTIPSYCHOTICS IN ARKANSAS MEDICAID PEDIATRIC
	Pathak P¹, West D², Martin BC², Helm M²
	1IMS Health, Falls Church, VA, USA, 2University of Arkansas for Medical Sciences, Little Rock, AR, USA

PMH71	PREVALENCE OF CONCOMITANT USE OF ANTICHOLINERGIC MEDICATIONS AND CHOLINESTERASE INHIBITORS IN A MEDICAID NURSING HOME POPULATION
	Modi A¹, Weiner M², Sands L1, Rosenman M3, Craig B1, Thomas III J1
	1Purdue University, Regenstrief Center for Healthcare Engineering, Center for Health Outcomes Research and Policy, West Lafayette, IN, USA, ²Indiana University, Indiana University Center for Aging Research, Regenstrief Institute Inc, Indianapolis, IN, USA, 3Indiana University, Regenstrief Institute Inc, Indianapolis, IN, USA

PMH72	OFF-LABEL USE OF SECOND-GENERATION ANTIPSYCHOTICS AMONG ADULT PATIENTS WITH BIPOLAR DISORDER IN A LARGE MANAGED CARE POPULATION
	Demland JA, Jing Y, Kelton CM, Guo JJ, Wigle PR
	University of Cincinnati, Cincinnati, OH, USA

PMH73	INITIATION OF ATOMOXETINE VS. STIMULANTS FOR CHILDREN WITH ADHD IN MEDICAID SETTINGS
	Van Brunt D¹, Ye W1, Pohl G1, Von Allmen H²
	1Eli Lilly and Company, Indianapolis, IN, USA, ²IMS Health, Blue Bell, PA, USA

PMH74	IMPACT OF ALTERNATIVE TREATMENTS ON POST TREATMENT COSTS FOR PATIENTS WITH BIPOLAR DISORDER
	Ganapathy V¹, McCombs JS², Stafkey-Mailey D1, Kim E3, Pikalov A4
	1University of Southern California School of Pharmacy, Los Angeles, CA, USA, 2University of Southern California, Los Angeles, CA, USA, 3Bristol-Myers Squibb, Plainsboro, NJ, USA, 4Otsuka America Pharmaceuticals, Rockville, MD, USA

PMH75	IMPACT OF ALTERNATIVE TREATMENTS ON POST-TREATMENT COSTS FOR PATIENTS WITH SCHIZOPHRENIA
	Zolfaghari S¹, McCombs JS², Stafkey-Mailey D3, Ganapathy V3, Kim E4, Pikalov A5
	1University of Southern California, School of Pharmacy, Los Angeles, CA, USA, 2University of Southern California, Los Angeles, CA, USA, 3University of Southern California School of Pharmacy, Los Angeles, CA, USA, 4Bristol-Myers Squibb, Plainsboro, NJ, USA, 5Otsuka America Pharmaceuticals, Rockville, MD, USA

PMH76	COST ESTIMATION OF PSYCHIATRIC CARE IN THE JAPANESE HOSPITAL USING SYSTEM DYNAMICS SIMULATION
	Nakahara N¹, Kobayashi M², Kamae I3, Inagaki A3
	1Eli Lilly Japan K.K, Kobe, Japan, ²Crecon Research and Consulting Inc, Shibuya-ku, Tokyo, Japan, 3Keio University Graduate School of Health Management, Fujisawa, Kanagawa-ken, Japan

PMH77	ANTIPSYCHOTIC METABOLIC PROPENSITY AND POLYTHERAPY: INFLUENCE ON HOSPITALIZATION
	Simoni-Wastila L¹, Shaffer T1, Hsu VD1, Mullins CD1, Qian J1, Yang HWK1, Chen CC², Kim E², Whitehead R3
	1University of Maryland School of Pharmacy, Baltimore, MD, USA, ²Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Otsuka America Pharmaceutical Inc, Rockville, MD, USA

PMH78	EFFECTS OF DIRECT-TO-CONSUMER ADVERTISING AND DETAILING SPENDING ON ANTIDEPRESSANT SWITCH AND TREATMENT COMPLETION
	Chen SY, Hansen R, Maciejewski ML
	University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PMH79	PHYSICAL MORBIDITY AMONG PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF THE NATIONAL HOSPITAL DISCHARGE REGISTRY
	Bouza C, Lopez T, Amate J
	Carlos III Health Institute, Madrid, Spain

PMH80	THE CHANGE OF PRICES AND EXPENDITURES OF THE ORIGINAL AND GENERIC DRUGS OF FLUOXETINE – A LONGITUDINAL ANALYSIS ON REIMBURSEMENT DATABASE OF THE NATIONAL HEALTH INSURANCE
	Lee CF¹, Liou WS², Hsieh SC3
	1Tri-Service General Hospital, Taipei, Taiwan, 2Medical Affair Bureau, MND, Taipei, Taiwan, 3National Taiwan University College of Public Health, Taipei City, Taiwan

PMH81	EXAMINING THE PERCEIVED BURDEN OF PRIOR AUTHORIZATION OF PSYCHOTHERAPEUTICS AMONG TEXAS MEDICAID PRESCRIBERS
	Brown C¹, Rascati KL1, Nwokeji ED1, Corbell ZD1, Phillips GA², Zachry WM²
	1The University of Texas at Austin, Austin, TX, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PMH82	PREVALENCE AND PATTERNS OF NEWER ANTIDEPRSSANTS USED IN CHILDREN AND ADOLESCENTS IN A STATE MEDICAID PROGRAM OVER SEVEN YEARS
	Helm ME, Luthra R, Hu P, Martin BC
	University of Arkansas for Medical Sciences, Little Rock, AR, USA

PMH83	USING RETAIL PHARMACY PRESCRIPTION DATA TO INVESTIGATE THE SEASONALITY OF ADHD TREATMENT: JANUARY 2003-OCTOBER 2007
	Lenderts SE¹, Cascade EF1, Kalali A²
	1Quintiles, Inc, Falls Church, VA, USA, 2Quintiles, Inc, San Diego, CA, USA

PMH84	PREDICTORS OF TREATMENT INITIATION OF DULOXETINE VS. VENLAFAXINE XR FOR PATIENTS WITH MAJOR DEPRESSION DISORDER IN MANAGED CARE SETTINGS
	Ye W, Zhao Y, Swindle R, Robinson RL
	Eli Lilly and Company, Indianapolis, IN, USA

PMH85	PSYCHOTHERAPY AND MEDICATION USE AMONG DEPRESSION PATIENTS
	Rhee Y¹, Taitel MS², Jordan N1
	1Northwestern Univeristy, Chicago, IL, USA, 2Matria Healthcare, Rosemont, IL, USA

PMH86	THE STANDARDS FOR BIPOLAR EXCELLENCE (STABLE) PROJECT: A BIPOLAR DISORDER QUALITY IMPROVEMENT INITIATIVE TO DEVELOP AND VALIDATE EVIDENCE-BASED PERFORMANCE MEASURES FOR ENDORSEMENT BY THE NATIONAL QUALITY FORUM (NQF)
	Jewell M¹, Golden W², Keck P3, Harshaw Q1, Shillington A1, Williams JW4, Brewster C1
	1EPI-Q, Oak Brook, IL, USA, ²Arkansas Foundation for Medical Care, Little Rock, AR, USA, 3University of Cincinnati, Cincinnati, OH, USA, 4Duke University Medical Center and Durham VA Medical Center, Durham, NC, USA

PMH87	SUPPORTING PRODUCT CLAIMS IN DRUG DEVELOPMENT: A FRAMEWORK FOR INTEGRATING PATIENT REPORTED OUTCOMES AND HEALTH ECONOMICS CONCEPTS AND ENDPOINTS
	Donatti C¹, Wild D1, Briggs A², Sculpher MJ3
	1Oxford Outcomes Ltd, Oxford, UK, 2University of Glasgow, Glasgow, UK, 3University of York, York, UK

NEUROLOGICAL DISORDERS Clinical Outcomes Studies

PND1	PREVALENCE AND COSTS OF COMORBIDITIES AMONG PERSONS WITH AND WITHOUT MULTIPLE SCLEROSIS: AN ANALYSIS OF THE AHRQ MAJOR AND SPECIFIC DIAGNOSTIC CATEGORIES
	Brook RA¹, Rajagopalan K², Kleinman NL3, Melkonian AK4
	1The JeSTARx Group, Newfoundland, NJ, USA, ²Biogen Idec Pharmaceuticals, Cambridge, MA, USA, 3HCMS Group, Paso Robles, CA, USA, 4The HCMS Group, Cheyenne, WY, USA

PND2	THE FABRY OUTCOME SURVEY (FOS): A DATABASE OF PROSPECTIVE OBSERVATIONS ON THE NATURAL HISTORY AND MANAGEMENT OF A RARE DISEASE
	Clarke J¹, Beck M², Giugliani R3, Sunder-Plassmann G4, Linhart A5, Hernberg-Ståhl E6, Mehta A7
	1Hospital for Sick Children, Toronto, Ontario, Canada, 2University of Mainz, Mainz, Germany, 3Hospital de Clinicas/UFRGS, Porto Alegre, RS, Brazil, 4Medical University Vienna, Vienna, Austria, 5Charles University, Prague, Czech Republic, 6Shire Human Genetic Therapies, Danderyd, Sweden, 7Royal Free Hospital, London, UK

PND3	WITHDRAWN

PND4	TRENDS AMONG HOSPITALIZED CYSTIC FIBROSIS PATIENTS
	Stevenson HM, Cerrtio P
	University of Louisville, Louisville, KY, USA

PND5	SUBSTANCE ABUSE AMONG PATIENTS DIAGNOSED WITH INSOMNIA
	Boulanger L¹, Doan J², Pashos CL1
	1Abt Associates Inc, Lexington, MA, USA, 2Takeda Pharmaceuticals North America, Inc, Deerfield, IL, USA

NEUROLOGICAL DISORDERS Cost Studies
PND6	MODELING THE IMPACT OF A FIXED-DOSE COMBINATION OF SUMATRIPTAN AND NAPROXEN SODIUM ON TRIPTAN CONSUMPTION IN A US MANAGED CARE POPULATION
	Smith TW¹, Kowal-Podmore S1, Runken MC²
	1IMS Consulting, Falls Church, VA, USA, ²GlaxoSmithKline, Research Triangle Park, NC, USA

PND7	BUDGET IMPACT OF TRANSDERMAL ADHESIVES OF RIVASTIGMINE IN BRAZILIAN PUBLIC HEALTH SYSTEM
	Bueno RLP¹, Gomes M², Indelli B²
	1FEI, São Paulo, Brazil, 2Novartis Biociências S/A, São Paulo, Brazil

PND8	MEDICAL COSTS ASSOCIATED WITH TREATMENT CHANGE IN MULTIPLE SCLEROSIS
	Nordstrom B¹, Seaman C1, Reynolds MW1, Rajagopalan K²
	1United BioSource Corporation, Medford, MA, USA, ²Biogen Idec Pharmaceuticals, Cambridge, MA, USA

PND9	COST-EFFECTIVENESS OF PREGABALIN IN PATIENTS WITH FIBROMYALGIA: A US PERSPECTIVE
	Vera-Llonch M1, Sadosky A², Chandran AB2, Oster G1
	1PAI, Brookline, MA, USA, 2Pfizer, Inc, New York, NY, USA

PND10	SWITCHING TO HIGH-DOSE HIGH-FREQUENCY INTERFERONS OR NATALIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS: A COST-EFFECTIVENESS ANALYSIS
	Fincher C¹, Meletiche D1, Goldberg LD²
	1EMD Serono, Inc, Rockland, MA, USA, ²Goldberg, MD & Associates, Battle Ground, WA, USA

PND11	TRIPTANS FOR ACUTE MIGRAINE: A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS STUDIES
	Membe S, Cimon K, McGahan L, Mierzwinski-Urban M
	Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada

PND12	COST-EFFECTIVENESS ASSESSMENT OF ANTIEPILEPTIC DRUGS AS ADJUVANT TREATMENTS FOR THE MANAGEMENT OF REFRACTORY PARTIAL SEIZURES IN ADULT MEXICAN PATIENTS
	Arreola-Ornelas H1, Dorantes-Aguilar J1, García-Mollinedo MDL², Rosado-Buzzo AA3, Mould-Quevedo J4, Davila-Loaiza G4
	1Fundación Mexicana para la Salud, Funsalud, Mexico City, Mexico, 2Links and Links S.A. de C. V, Mexico City, Mexico, 3Links & Links S.A. de C.V, Mexico City, Mexico, 4Pfizer Mexico, Mexico City, Mexico

PND13	A COST-EFFECTIVENESS ANALYSIS OF NATALIZUMAB VS. INTERFERON-BETA AND GLATIRAMER ACETATE IN PATIENTS WITH ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS CURRENTLY FAILING ON EXISTING THERAPY
	Gani R¹, Samuels ER², Hughes S3, Giovanonni G4
	1Heron Evidence Development Ltd, Hertfordshire, UK, ²Heron Evidence Development Ltd, Letchworth Garden City, Hertfordshire, UK, 3Biogen Idec Ltd, Maidenhead, Berkshire, UK, 4Barts and The London School of Medicine and Dentistry, London, UK

PND14	ECONOMIC EVALUATION OF SATIVEX® FOR TREATMENT OF NEUROPATHIC PAIN IN PATIENTS WITH MULTIPLE SCLEROSIS
	Mittmann N1, Isogai P1, McDonald HP2
	1HOPE Research Centre, Toronto, ON, Canada, ²Bayer Healthcare, Toronto, ON, Canada

PND15	COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS
	Caloyeras JP¹, Wang C², Bauer L3, Lee WC4, Lanius V3, Gondek K5
	1Abt Associates Inc, Lexington, MA, USA, ²Bayer Pharmaceuticals Corporation, Montville, NJ, USA, 3Bayer Schering Pharma AG, Berlin, P300, Germany, 4Abt Associates Inc, Bethesda, MD, USA, 5Bayer Pharmaceuticals Corporation, West Haven, CT, USA

PND16	THE CONCENTRATION AND PERSISTENCE OF HEALTH CARE EXPENDITURES AND PRESCRIPTION DRUG EXPENDITURES IN PATIENTS WITH ALZHEIMER'S DISEASE
	Lin PJ, Biddle AK, Maciejewski ML
	University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PND17	SEVERITY OF ILLNESS AMONG PERSONS WITH AND WITHOUT MULTIPLE SCLEROSIS: AN ANALYSIS OF COST QUINTILES
	Kleinman NL¹, Rajagopalan K², Brook RA3, Melkonian AK4
	1HCMS Group, Paso Robles, CA, USA, ²Biogen Idec Pharmaceuticals, Cambridge, MA, USA, 3The JeSTARx Group, Newfoundland, NJ, USA, 4The HCMS Group, Cheyenne, WY, USA

PND18	HIGHER INPATIENT COSTS AMONG PATIENTS WITH SUBARACHNOID HEMORRHAGE COMPLICATED BY VASOSPASM
	Chou CH¹, Reed SD1, Allsbrook JS1, Steele JL², Schulman KA1, Alexander MJ3
	1Duke Clinical Research Institute, Durham, NC, USA, ²Duke University Medical Center, Durham, NC, USA, 3Cedars-Sinai Neurovascular Center, Los Angeles, CA, USA

PND19	THE ECONOMIC IMPACT OF ACUTE MEDICATION OVERUSE AMONG PATIENTS WITH MIGRAINE OR HEADACHE: A MANAGED CARE PERSPECTIVE
	Pesa JA¹, Thayer S², Rupnow MF3, Biondi D3, Yaldo AZ⁴
	1Ortho-McNeil Janssen Scientific Affairs, LLC, Superior, CO, USA, 2i3 Innovus, San Francisco, CA, USA, 3Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 4Ortho-McNeil Janssen Scientific Affairs, Sterling Heights, MI, USA

PND20	ECONOMIC CONSEQUENCES OF MULTIPLE SCLEROSIS: A POPULATION-BASED STUDY
	Noyes K¹, Bajorska A1, Schwid S1, Holloway R1, Dick A²
	1University of Rochester School of Medicine, Rochester, NY, USA, 2The RAND Corporation, Pittsburgh, PA, USA

PND21	COST-UTILITY OF PRAMIPEXOL COMPARED WITH L-DOPA/CARBIDOPA IN THE TREATMENT OF PARKINSON'S DISEASE IN MEXICO
	Idrovo J1, Rivas R², Zapata L2
	1Guia Mark, Mexico, DF, Mexico, ²Guia Mark, México, DF, Mexico

PND22	THE COST OF DISABILITY AND MEDICALLY-RELATED ABSENTEEISM AMONG EMPLOYEES WITH MULTIPLE SCLEROSIS
	Birnbaum HG¹, Ivanova JI², Samuels S3, Davis M1, Phillips AL4, Meletiche D4
	1Analysis Group, Inc, Boston, MA, USA, ²Analysis Group, Inc, New York, NY, USA, 3Analysis Group Inc, Boston, MA, USA, 4EMD Serono, Inc, Rockland, MA, USA

PND23	MIGRAINE SUFFERERS SHOW SIGNIFICANT HEALTH CARE UTILIZATION AND EXPENDITURES
	Iyer RG, Fensterheim LE, Berger JE, Davis DL
	CVS\|Caremark Inc, Northbrook, IL, USA

NEUROLOGICAL DISORDERS Patient-Reported Outcomes
PND24	IMPACT OF NON-ADHERENCE TO ANTIEPILEPTIC DRUGS ON MORBIDITY
	Weiner JR¹, Duh MS1, Guérin A², Cunnington M3, Faught E4
	1Analysis Group, Inc, Boston, MA, USA, ²Groupe d'Analyse, Ltée, Montreal, QC, Canada, 3GlaxoSmithKline, Harlow, Essex, UK, 4University of Alabama, Birmingham, AL, USA

PND25	EXPLORING THE RELATIONSHIP BETWEEN DIFFERENT DISPENSING SYSTEMS AND MEDICATION COMPLIANCE AND PERSISTENCY IN MULTIPLE SCLEROSIS PATIENTS USING PHARMACY CLAIMS DATA
	Tang J, Faris R
	Accredo Health Group, Memphis, TN, USA

PND26	COMPARISON OF COMPLIANCE AND PERSISTENCE WITH IMMUNOMODULATING AGENTS FOR MULTIPLE SCLEROSIS IN A COMMERCIALLY INSURED POPULATION
	Shea T¹, Wood F², Shim B1, Becker E3, Meletiche D3, Bennett R3, AL-Sabbagh A3
	1IMS Management Consulting, Plymouth Meeting, PA, USA, 2PharMetrics, Inc., a unit of IMS, Watertown, MA, USA, 3EMD Serono, Inc, Rockland, MA, USA

PND27	RELATIONSHIP BETWEEN GAPS IN DRUG TREATMENT FOR MULTIPLE SCLEROSIS AND INCIDENCE OF EXACERBATIONS: FINDINGS FROM A NATIONAL MANAGED CARE DATABASE
	Okuda DT¹, Kozma C², Dickson M3, Meletiche D4
	1University of California, San Francisco, San Francisco, CA, USA, 2University of South Carolina, West Columbia, SC, USA, 3University of South Carolina, College of Pharmacy, Columbia, SC, USA, 4EMD Serono, Inc, Rockland, MA, USA

PND28	IMPROVEMENTS IN QUALITY OF LIFE FOLLOWING TREATMENT WITH BOTULINUM TOXIN TYPE A FOR CERVICAL DYSTONIA
	Carlton R1, Bramley T², Shah MV3, Hansen JE3
	1Xcenda, Palm Harbor, FL, USA, 2Xcenda, Salt Lake City, UT, USA, 3Allergan Inc, Irvine, CA, USA

PND29	REVIEW OF QUALITY OF LIFE INSTRUMENTS IN MIGRAINE
	Shah N¹, Kamal KM²
	1West Virginia University, Morgantown, WV, USA, 2Duquesne University, Pittsburgh, PA, USA

PND30	PERFORMANCE OF THE EURO QOL 5D (EQ-5D) IN PRIMARY CARE PATIENTS WITH CO-MORBID INSOMNIA
	Roy AN¹, Madhavan SS², Miller LA3, Lloyd A4
	1Walgreens Co, Deerfield, IL, USA, 2West Virginia University, Morgantown, WV, USA, 3University of Texas - MD Anderson Cancer Center, Houston, TX, USA, 4Oxford Outcomes, Oxford, UK

PND31	CO-MORBID INSOMNIA IN PRIMARY CARE PATIENTS AFFECTS HEALTH-RELATED QUALITY OF LIFE (HRQL) INDEPENDENT OF OTHER FACTORS
	Roy AN¹, Madhavan SS², Selby JB², Bradlyn A², Makela EH²
	1Walgreens Co, Deerfield, IL, USA, 2West Virginia University, Morgantown, WV, USA

PND32	DETERMINATION OF THE LONGITUDINAL VALIDITY AND MINIMALLY IMPORTANT DIFFERENCE OF THE 8-ITEM PARKINSON'S DISEASE QUESTIONNAIRE (PDQ-8)
	Zhao YJ¹, Tan LC², Lau PN², Au WL², Li SC3, Luo N4
	1National University of Singapore, Singapore, Singapore, Singapore, 2National Neuroscience Institute, Singapore, Singapore, 3University of Newcastle, Callaghan, NSW, Australia, 4National University of Singapore, Singapore, Singapore

PND33	IMPROVED QUALITY OF LIFE AMONG RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS TREATED LONG-TERM WITH GLATIRAMER ACETATE
	Oleen-Burkey M¹, Johnson KP²
	1Teva Neuroscience, Kansas City, MO, USA, 2University of Maryland, Baltimore, MD, USA

PND34	ASSOCIATION BETWEEN CHANGE IN OVERALL QUALITY OF LIFE (QOL), DISEASE LEVEL AND FUNCTIONAL STATUS SINCE NATALIZUMAB INITIATION
	Rajagopalan K¹, Stephenson JJ², Kamat S3
	1Biogen Idec Pharmaceuticals, Cambridge, MA, USA, ²HealthCore Inc, Wilmington, DE, USA, 3HealthCore, Wilmington, DE, USA

PND35	IMPACT OF NATALIZUMAB ON PATIENT OUTCOMES IN MULTIPLE SCLEROSIS: A CROSS-SECTIONAL SURVEY
	Stephenson JJ¹, Rajagopalan K², Kamat S1
	1HealthCore Inc, Wilmington, DE, USA, ²Biogen Idec Pharmaceuticals, Cambridge, MA, USA
PND36	OBSERVED DIFFERENCES BETWEEN DAILY DIARY AND WEEKLY REPORT OF CYSTIC FIBROSIS SYMPTOMS
	Bennett AV¹, Patrick DL1, Edwards TC1, Lymp JF², Goss CH3
	1University of Washington, Seattle, WA, USA, ²Children's Hospital and Regional Medical Center, Seattle, WA, USA, 3University of Washington Medical Center, Seattle, WA, USA

PND37	REDUCTIONS IN FREQUENCY AND INTENSITY OF PAIN WITH BOTULINUM TOXIN TYPE A FOR THE TREATMENT OF CERVICAL DYSTONIA
	Shah MV¹, Carlton R², Bramley T3
	1Allergan, Inc, Irvine, CA, USA, 2Xcenda, Palm Harbor, FL, USA, 3Xcenda, Salt Lake City, UT, USA

PND38	EVALUATION OF INTERVIEWER TRAINING FOR AN INTERVIEWER ADMINISTERED PATIENT-REPORTED OUTCOME IN A GLOBAL CLINICAL TRIAL
	Dries J, Butler AJ, Busner J
	United BioSource Corporation, Wayne, PA, USA

PND39	PATIENT- AND PHYSICIAN-ASSESSED FUNCTIONAL DISABILITY IN PATIENTS TREATED WITH BOTULINUM TOXIN TYPE A FOR CERVICAL DYSTONIA
	Bramley T¹, Shah MV², Carlton R3
	1Xcenda, Salt Lake City, UT, USA, ²Allergan, Inc, Irvine, CA, USA, 3Xcenda, Palm Harbor, FL, USA

PND40	PHYSICAL AND PATIENT REPORTED OUTCOMES IN MULTIPLE SCLEROSIS
	Kirzinger S¹, Nichol MB², Jones J3
	1University of Louisville, Louisville, KY, USA, 2University of Southern California, Los Angeles, CA, USA, 3Bayer Healthcare Pharmaceuticals, Wayne, NJ, USA

PND41	PHYSICIAN AND PATIENT REPORTED OUTCOMES REVEAL RAPID ONSET OF IMPROVEMENT AND OVERALL CONVENIENCE, TOLERABILITY AND EASE-OF-USE WITH RASAGILINE IN PARKINSON'S DISEASE (PD) IN LEGATO
	Castelli-Haley J¹, Conner JB1, Salzman PM²
	1Teva Neuroscience, Kansas City, MO, USA, 2Teva Neuroscience, Horsham, PA, USA

PND42	THE DEVELOPMENT OF A PATIENT SATISFACTION INSTRUMENT FOR INSOMNIA: A PSYCHOMETRIC APPROACH
	Vander Wal G¹, Szeinbach SL², Doan J³, Lichstein K1
	1The University of Alabama, Tuscaloosa, AL, USA, 2The Ohio State University, Columbus, OH, USA, 3Takeda Global Research and Development Center, Deerfield, IL, USA

PND43	LEVEL OF SATISFACTION OF SPANISH MULTIPLE SCLEROSIS PATIENTS TREATED WITH A NEW FORMULATION OF AVONEX® (INTERFERON BETA-1A 30 MCG INTRAMUSCULAR, ONCE WEEKLY, SOLUTION FOR INJECTION READY TO USE)
	Sánchez-Soliño O, Arroyo E, Grau C
	Biogen Idec Iberia, S.L, Madrid, Spain

NEUROLOGICAL DISORDERSHealth Care Use & Policy Studies
PND44	CANADIAN PATIENT SURVEY TO ASSESS PATIENTS' PLIGHT TO DYSTONIA DIAGNOSES AND BOTULINUM TOXIN TYPE A TREATMENT
	Simonyi S¹, Jog M², The Canadian Movement Disorders Survey Group N3
	1Allergan Inc, Markham, ON, Canada, 2London Health Sciences Centre, London, ON, Canada, 3', ', Canada

PND45	USE OF DISEASE-MODIFYING DRUGS IN MULTIPLE SCLEROSIS: A POPULATION BASED STUDY
	Noyes K¹, Bajorska A1, Schwid S1, Holloway R1, Dick A²
	1University of Rochester School of Medicine, Rochester, NY, USA, 2The RAND Corporation, Pittsburgh, PA, USA

PND46	THE RISKS OF MULTIPLE GENERIC SUBSTITUTION OF ANTIEPILEPTIC DRUGS : THE CASE OF TOPIRAMATE
	Lelorier J¹, Duh MS², Paradis PE3, Latremouille-Viau D4, Sheehy O5, Greenberg P², Lee SP6, Rupnow MF7
	1Universite de Montreal, Montreal, QC, Canada, ²Analysis Group, Inc, Boston, MA, USA, 3Groupe d'analyse, Ltd, Montreal, QC, Canada, 4Groupe d'analyse, Ltee, Montreal, QC, Canada, 5Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, 6Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 7Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA

PND47	ARE THERE GENDER AND ETHNIC DISPARITIES IN THE USE OF INSOMNIA PRESCRIPTIONS?
	Lai L, Huang CY, Massante M
	Nova Southeastern University, Ft. Lauderdale, FL, USA

PND48	WITHDRAWN

SYSTEMIC DISORDERS/CONDITIONS Clinical Outcomes Studies

PSY1	META-ANALYSIS OF ANTICONVULSANTS, SNRIS AND TCAS IN TREATING NEUROPATHIC PAIN
	Einarson TR¹, Walker J1, Machado M², Iskedjian M1
	1PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, 2University of Toronto, Toronto, ON, Canada

PSY2	THE DEVELOPMENT OF A STANDARDIZED CLINICAL ALGORYTHMIC PREDICTOR OF WEIGHT LOSS AFTER BARIATRIC SURGERY: DATABASE ANALYSIS ENABLES EMPIRICAL AND STATISTICAL PREDICTION OF THRESHOLD WEIGHT LOSS BY END OF THIRD POST-OPERATIVE PHYSICIAN VISIT
	Hayward A¹, Roggenbach MMW1, Purdy C1, Einarson TR², Iskedjian M1
	1PharmIdeas, Buffalo, NY, USA, 2University of Toronto, Toronto, ON, Canada

PSY3	A META-ANALYSIS OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS OF THE EFFICACY OF BOTULINUM TOXIN A FOR THE PROPHYLAXIS OF CHRONIC MIGRAINE HEADACHES
	Shuhendler AJ, Lee S, Siu M, Ondovcik SL, Lam K, Alabdullatif A, Zhang X, Machado M, Einarson TR
	University of Toronto, Toronto, ON, Canada

PSY4	THE BALANCE BETWEEN SEVERE CARDIOVASCULAR AND GASTROINTESTINAL EVENTS AMONG USERS OF SELECTIVE AND NON-SELECTIVE NON STEROIDAL ANTI-INFLAMMATORY DRUGS
	Van der Linden MW¹, Van der Bij S², Welsing P3, Kuipers E4, Herings RM5
	1PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands, 2PHARMO Institute, Utrecht, Utrecht, Netherlands, 3Pfizer BV, Capelle a/d Ijssel, ZH, Netherlands, 4Erasmus University Medical Center, Rotterdam, Netherlands, 5PHARMO Institute, Utrecht, Netherlands

PSY5	CROSS-CULTURAL COMPARISONS OF THE OVERWEIGHT/OBESE POPULATION IN THE US AND EUROPE
	Annunziata K¹, Gupta S1, Chapnick J1, Pokras S², Klingman D²
	1Consumer Health Sciences, Princeton, NJ, USA, ²IMS Consulting, Falls Church, VA, USA

PSY6	THE PREVALENCE OF PAIN SYMPTOMS AMONG UNITED STATES ADULTS AGED 65 AND OLDER
	McDonald M¹, Hertz RP1, Unger AN1, Lustik MB²
	1Pfizer Inc, New York, NY, USA, 2Science Applications International Corporation, Reston, VA, USA

PSY7	BURDEN OF OBESITY: 10-YEAR REVIEW OF PUBLISHED LITERATURE ON OBESITY PREVALENCE IN NINE COUNTRIES
	Barrett AM¹, Boye KS², Oyelowo O²
	1RTI Health Solutions, RTP, NC, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PSY8	THE ECONOMIC BURDEN OF SYSTEMIC LUPUS ERYTHEMATOSUS AMONG PATIENTS OF THE CAROLINA LUPUS STUDY EARLY IN THE COURSE OF DISEASE
	Campbell Jr R¹, Cooper GS², Gilkeson GS3
	1Medical University of South Carolina, Charleston, SC, USA, 2US Environmental Protection Agency, Washington, DC, USA, 3Medical University of South Carolina/ Ralph Johnson Medical Center, Charleston, SC, USA

PSY9	RISK FACTORS AND RISKS ASSOCIATED WITH HOSPITAL STAYS IN PATIENTS WITH MYALGIA
	Justice EE, Cerrito PB
	University of Louisville, Louisville, KY, USA

PSY10	A NOVEL APPROACH TO ADJUST FOR THE IMPACT ON SURVIVAL RESULTING FROM PATIENT CROSS-OVER FROM CONTROL TO EXPERIMENTAL TREATMENT IN CLINICAL TRIALS
	Ishak KJ¹, Deniz B², Drayson M3, Morgan GJ4, Augustson BM5, Child JA6, Begum G7, Dunn JA7, Shearer A8, Caro JJ²
	1United BioSource Corporation, Montreal, QC, Canada, 2United BioSource Corporation, Concord, MA, USA, 3University of Birmingham, Birmingham, UK, 4The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research, Surrey, UK, 5Sir Charles Gairdner Hospital, Nedlands, Australia, 6University of Leeds, Leeds, UK, 7Warwick Medical School, Coventry, UK, 8Celgene UK & Ireland, Windsor, UK

PSY11	EVALUATION OF ACETAMINOPHEN EXPOSURES REPORTED TO A REGIONAL POISON CONTROL CENTER FOR ADULT PATIENTS
	Angalakuditi MV1, Coley K², Krenzelok E3
	1Convatec, A Bristol-Myers Squibb Company, Skillman, NJ, USA, 2University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA, 3University of Pittsburgh and Pittsburgh Poison Control Center, Pittsburgh, PA, USA

SYSTEMIC DISORDERS/CONDITIONS Cost Studies
PSY12	PROJECTED COST OF CARDIOMETABOLIC RISK FACTORS IN COMMERCIALLY INSURED NORMAL AND OVERWEIGHT PRIMARY CARE PATIENTS
	Ghate S¹, Said Q², Huse D3, Ben-Joseph R4, Brixner D5
	1University of Utah, Salt Lake City, UT, USA, 2University of Arkansas for Medical Sciences, Little Rock, AR, USA, 3Thomson Medstat, Cambridge, MA, USA, 4Sanofi-Aventis, Bridgewater, NJ, USA, 5The University of Utah College of Pharmacy, Salt Lake City, UT, USA

PSY13	THE HEALTH CARE COST EFFECTS OF DIABETES AMONG OBESE AND MORBIDLY OBESE ADULTS IN THE UNITED STATES
	Cawley J¹, Rizzo JA², Haas K3
	1Cornell University, Ithaca, NY, USA, 2Stony Brook University, Stony Brook, NY, USA, 3Ethicon Endo-Surgery, Cincinnati, OH, USA

PSY14	ECONOMIC EVALUATION OF LENOLIDOMIDE USE FOR MULTIPLE MYELOMA IN SCOTLAND IN PATIENTS WHO HAVE RECEIVED ONE PRIOR THERAPY
	Deniz B1, Ishak KJ², Shearer A3, Dale P4, Caro JJ¹
	1United BioSource Corporation, Concord, MA, USA, 2United BioSource Corporation, Montreal, QC, Canada, 3Celgene Corporation, Windsor, UK, 4United Biosource, London, England, UK

PSY15	COST-EFFECTIVENESS OF ERYTHROPOIESIS STIMULATING AGENT THERAPY BY HEMOGLOBIN TARGETS IN CHRONIC KIDNEY DISEASE
	An JJ, Hay JW
	University of Southern California, Los Angeles, CA, USA

PSY16	COST-EFFECTIVENESS OF TRANSDERMAL OPIOIDS REGARDING OPIOID-RELATED FRACTURES IN GERMANY – A MODEL APPROACH
	Hass B1, Lungershausen J1, Hertel N1, Kotowa W1, Poulsen Nautrup B², Liedgens H3
	1IMS HEALTH, Nuremberg, Germany, ²EAH Consulting, Juelich, Northrhine Westf, Germany, 3Grünenthal GmbH, Aachen, Germany

PSY17	THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN MEXICO
	Juarez-Garcia A¹, Zapata L², Vega G², Idrovo J², Rivas R², Kramis JL1, Litalien G3, Rangel S1
	1Bristol-Myers Squibb, México City, Mexico, ²Guia Mark, México City, Mexico, 3Bristol Myers Squibb Pharmaceutical, Wallingford, CT, USA

PSY18	A COMPARATIVE COST-EFFECTIVENESS ANALYSIS ON THE USE OF FLECTOR® PATCH (DICLOFENAC EPOLAMINE TOPICAL PATCH) 1.3% VERSUS LIDODERM® (LIDOCAINE PATCH 5%) FOR THE TREATMENT OF ACUTE PAIN FOLLOWING INJURY
	Carter CA¹, Dunsworth GA1, Brookfield RB²
	1Pharmaceutical Strategic Initiatives, LLC, Research Triangle Park, NC, USA, ²Alpharma Pharmaceuticals, LLC, Piscataway, NJ, USA

PSY19	PHARMACOECONOMIC EVALUATION OF TREATMENT OF HAIRY CELL LEUKEMIA
	Krysanov I¹, Moiseeva TN², Al-Radi LS², Khabriev RU1, Yagudina RI1
	1Moscow Medical Academy, Moscow, Russia, ²Hematological Scientific Center of the Russian Academy of Medical Sciences, Moscow, Russia

PSY20	COST-EFFECTIVENESS ANALYSIS OF IMMUNOSUPPRESSIVE TREATMENTS FOR BONE MARROW TRANSPLANTATION IN PATIENTS WITH APLASTIC ANEMIA IN MEXICO
	Mould-Quevedo J¹, Contreras-Hernandez I², Salinas-Escudero G3, Davila-Loaiza G1
	1Pfizer Mexico, Mexico City, Mexico, 2Social Security Mexican Institute, Mexico City, Mexico, 3Hospital Infantil de México Federico Gomez, Mexico City, Mexico

PSY21	THE COST-EFFECTIVENESS OF LYRICA (PREGABALIN) IN PATIENTS WITH CENTRAL NEUROPATHIC PAIN
	Ramos É, Tran T, Landry PA
	Pfizer Canada Inc, Kirkland, QC, Canada

PSY22	COST-EFFECTIVENESS OF PREGABALIN COMPARED TO GABAPENTIN IN TREATMENT OF PATIENTS WITH POSTHERPETIC NEURALGIA
	Ragnarson Tennvall G¹, Sandelin R²
	1IHE, Lund, Sweden, 2Pfizer AB, Sollentuna, Sweden

PSY23	COST-EFFECTIVENESS OF LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING AND LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS IN THE TREATMENT OF MORBID OBESITY
	Campbell J¹, McGarry LJ1, Thompson D1, Gilmore K1, Hill G1, Lee J², Hale B3, Shikora S4, Weinstein MC5
	1i3 Innovus, Medford, MA, USA, ²Allergan Pharmaceuticals, Franklin, TN, USA, 3Allergan Pharmaceuticals, Irvine, CA, USA, 4Tufts-New England Medical Center, Boston, MA, USA, 5i3 Innovus Research Inc., Harvard School of Public Health, Harvard Medical School, Boston, MA, USA

PSY24	THE ECONOMIC CONSEQUENCES OF POST OPERATING PAIN MANAGEMENT WITH TRANSDERMAL FENTANYL (IONSYS) VERSUS INTRAVENOUS PATIENT-CONTROLLED ANALGESIA
	Liwing J1, Löthgren M¹, Ragnarson Tennvall G², Wennberg E3
	1Jansen-Cilag AB, Sollentuna, Sweden, ²IHE, Lund, Sweden, 3Sahlgrenska University Hospital, Gothenburg, Sweden

PSY25	ECONOMIC IMPACT AND CONSERVATION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) THROUGH THERAPEUTIC SUBSTITUTION WITH ANTI-D IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIA PURPURA (ITP) AT AN URBAN TEACHING HOSPITAL IN STATEN ISLAND, NY
	Coyne M
	Staten Island University Hospital, Staten Island, NY, USA

PSY26	THE DIRECT MEDICAL COSTS ASSOCIATED WITH SUSPECTED (CONFIRMED AND NEGATIVE) HEPARIN-INDUCED THROMBOCYTOPENIA
	Nanwa N¹, Mittmann N², Knowles S², Selby R², Shear N1, Bucci C², Walker S1, Geerts W²
	1University of Toronto, Toronto, ON, Canada, 2Sunnybrook Health Sciences Centre, Toronto, ON, Canada

PSY27	BURDEN OF OBESITY: 10-YEAR REVIEW OF PUBLISHED LITERATURE ON DIRECT AND INDIRECT COSTS IN NINE COUNTRIES
	Barrett AM¹, Colosia A1, Boye KS², Oyelowo O²
	1RTI Health Solutions, RTP, NC, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PSY28	A SYSTEMATIC REVIEW OF LOW BACK PAIN COST OF ILLNESS STUDIES IN THE UNITED STATES AND INTERNATIONALLY
	Dagenais S¹, Caro JJ², Haldeman S3
	1CAM Research Institute / University of Ottawa, Rockcliffe, ON, Canada, 2UBC, Concord, MA, USA, 3UCI / UCLA, Santa Ana, CA, USA

PSY29	THE DIRECT AND INDIRECT COSTS OF OBESITY IN AN EMPLOYED POPULATION
	Durden ED¹, Ben-Joseph R², Huse D1, Chu BC3
	1Thomson Healthcare, Cambridge, MA, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3Thomson Healthcare, Santa Barbara, CA, USA

PSY30	EVALUATION OF COST AND OUTCOMES OF WEIGHT CONTROL PROGRAM IN A REGIONAL HOSPITAL AT SOUTHERN TAIWAN
	Yen JMC¹, Yang YH², Yen CH3
	1E-DA Hospital/I-SHOU University, Yan-Chau Shiang, Kaohsiung County, Taiwan, 2Kaohsiung Medical University,Graduate Institute of Oral Health Science, Kaohsiung, Taiwan, 3Kaohsiung Medical University, School of Dentistry, Kaohsiung, Taiwan

PSY31	GREATER SEVERITY OF ILLNESS, RISK OF MORTALITY, LENGTH-OF-STAY, AND HOSPITAL COSTS IN PATIENTS WITH HYPONATREMIA
	Ernst FR¹, Seal B², Richmond M1
	1Premier, Inc, Charlotte, NC, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA

PSY32	COST-UTILITY STUDY OF RECOMBINANT FACTOR VIII IN THE TREATMENT OF HEMOPHILIA A IN MEXICO
	Soria-Cedillo IF¹, De la Mora-Chávez T², Del Campo-Pérez M², Brugada-Cruces C², Garcia-Contreras F²
	1Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico, ²Instituto Mexicano del Seguro Social, Mexico City, Mexico

PSY33	WITHDRAWN

PSY34	COST-UTILITY ANALYSIS OF SUBCUTANEOUS VERSUS INTRAVENOUS IMMUNOGLOBULIN
	Membe S, Ho C, Cimon K, Morrison A
	Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada

PSY35	PREVALENCE OF METABOLIC SYNDROME AND ITS IMPACT ON HEALTH CARE RESOURCE UTILIZATION
	Kannan H, Bolge SC
	Consumer Health Sciences, Princeton, NJ, USA

PSY36	COMPLEMENTARY AND ALTERNATIVE MEDICINE AND HEALTH CARE UTILIZATION IN PATIENTS WITH NON-CANCER CHRONIC PAIN
	Liao D, Richardson D, Singh V, Pizzi LT
	Jefferson Medical College, Philadelphia, PA, USA

PSY37	RESOURCE USE AND COSTS ASSOCIATED WITH BACK PAIN IN GERMANY
	Greiner W, Damm O, Bowles D
	University of Bielefeld, Bielefeld, NRW, Germany

SYSTEMIC DISORDERS/CONDITIONS Patient-Reported Outcomes
PSY38	FACTORS ASSOCIATED WITH LOWER HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN ADULTS WITH FACTOR VIII DEFICIENCY - THE HEMOPHILIA UTILIZATION GROUP STUDY-PART V (HUGS-V)
	Zhou ZY¹, Wu J1, Globe D², Gwadry-Sridhar F3, Riske B4, Ullman M5, Huszti H6, Koerper M7, Baker J8, Johnson KA1
	1University of Southern California, Los Angeles, CA, USA, ²Amgen, Thousand Oaks, CA, USA, 3University of Western Ontario, London, ON, Canada, 4University of Colorado Health Sciences Center, Aurora, CO, USA, 5Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA, 6Children's Hospital of Orange County, Orange, CA, USA, 7University of California, San Francisco, San Francisco, CA, USA, 8Children's Center for Cancer and Blood Disorders, Los Angeles, CA, USA

PSY39	HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH HEMOPHILIA AND INHIBITORS
	Lee WC¹, Brown M², Joshi AV3, Foster T², Pashos CL²
	1Abt Associates Inc, Bethesda, MD, USA, ²Abt Associates Inc, Lexington, MA, USA, 3Novo Nordisk Inc, Princeton, NJ, USA

PSY40	SYSTEMATIC REVIEW OF THE PSYCHOMETRIC PROPERTIES OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY – ANEMIA (FACT-AN) FOR ANEMIC CANCER PATIENTS
	An JJ¹, Gwadry-Sridhar F²
	1University of Southern California, Los Angeles, CA, USA, 2University of Western Ontario, London, Ontario, Canada

PSY41	PATIENT- AND CAREGIVER-REPORTED PREFERENCES FOR CHARACTERISTICS OF TREATMENTS FOR HEMOPHILIA PATIENTS WITH INHIBITORS
	Lee WC¹, Brown M², Joshi AV3, Foster T², Pashos CL²
	1Abt Associates Inc, Bethesda, MD, USA, ²Abt Associates Inc, Lexington, MA, USA, 3Novo Nordisk Inc, Princeton, NJ, USA

PSY42	EFFECTIVENESS OF ONCE-DAILY EXTENDED-RELEASE (ER) TRAMADOL IN ACHIEVING CLINICALLY MEANINGFUL IMPROVEMENT IN FUNCTIONING
	Janagap C¹, Lee SP², Mody S1, Ng DB3, Schein JR1
	1Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 3Ortho-McNeil Janssen Scientific Affairs, LLC, Chicago, IL, USA

PSY43	DISCOVERING THE STRUCTURE OF THE POWER OF FOOD SCALE (PFS) IN OBESE PATIENTS
	Cappelleri JC¹, Bushmakin AG1, Gerber RA², Leidy NK3, Sexton C3, Karlsson J4, Lowe MR5
	1Pfizer Inc, Groton, CT, USA, 2Pfizer Inc, New London, CT, USA, 3United BioSource Corporation, Bethesda, MD, USA, 4Sahlgrenska Academy at Göteborg University, Göteborg, Sweden, 5Drexel University, Philadelphia, PA, USA

PSY44	LINGUISTIC VALIDATION OF THE HAEMO-QOL AND HAEM-A-QOL FOR USE IN INTERNATIONAL STUDIES
	Chevallet L¹, Weatherall JH², Von Mackensen S3
	1Mapi Research Institute, Lyon, Rhone, France, 2Novo Nordisk, Bagsværd, Denmark, 3Institute of Medical Psychology, München, Germany

PSY45	EVALUATION OF THE NEUROPATHIC PAIN SYMPTOM INVENTORY: CONCEPTUAL ADEQUACY IN SIX COUNTRIES
	Crawford B¹, Bouhassira D², Wong A3, Dukes E4
	1Mapi Values, Tokyo, Meguro, Japan, ²Hôpital Ambroise Paré, Boulogne-Billancourt, France, 3Mapi Values, Boston, MA, USA, 4Pfizer, New York, NY, USA

PSY46	PSYCHOMETRIC ANALYSIS OF THE THREE-FACTOR EATING QUESTIONNAIRE: RESULTS FROM A LARGE DIVERSE SAMPLE OF OBESE AND NON-OBESE SUBJECTS
	Cappelleri JC¹, Bushmakin AG1, Gerber RA², Leidy NK3, Sexton C3, Lowe MR4, Karlsson J5
	1Pfizer Inc, Groton, CT, USA, 2Pfizer Inc, New London, CT, USA, 3United BioSource Corporation, Bethesda, MD, USA, 4Drexel University, Philadelphia, PA, USA, 5Sahlgrenska Academy at Göteborg University, Göteborg, Sweden

PSY47	IMPACT OF NIGHTTIME PAIN ON SLEEP QUALITY IN PATIENTS WITH CHRONIC PAINFUL CONDITIONS
	Chaudhari PK, Richardson DM, Singh VP, Pizzi LT
	Jefferson Medical College, Philadelphia, PA, USA

PSY48	IMPACT OF IMMUNE THROMBOCYTOPENIC PURPURA ON HEALTH CARE RESOURCE USE AND WORKPLACE PRODUCTIVITY
	Young JW¹, Deuson R², Isitt J²
	1Platelet Disorder Support Association, Rockville, MD, USA, ²Amgen, Thousand Oaks, CA, USA

PSY49	THE WILLINGNESS TO PAY TO MINIMIZE CHRONIC PAIN
	Chuck A¹, Adamowicz W², Jacobs P1, Ohinmaa A², Dick B², Rashiq S²
	1Institute of Health Economics, Edmonton, AB, Canada, 2University of Alberta, Edmonton, AB, Canada

SYSTEMIC DISORDERS/CONDITIONS Health Care Use & Policy Studies
PSY50	PHYSICIANS' INTENTIONS TO MEASURE BODY MASS INDEX IN CHILDREN AND ADOLESCENTS: A THEORY OF REASONED ACTION MODEL
	Khanna R¹, Scott V1, Kavookjian J1, Kamal KM², Miller LA3, Neal WA1
	1West Virginia University, Morgantown, WV, USA, ²Duquesne University, Pittsburgh, PA, USA, 3University of Texas - MD Anderson Cancer Center, Houston, TX, USA

PSY51	THE EFFECTS OF COMORBIDITY, PRESCRIPTION DRUG USE, AND MEDICAL UTILIZATION ON DULOXETINE INITIATION IN PATIENTS WITH FIBROMYALGIA
	White LA¹, Birnbaum H1, Samuels S¹, Kaltenboeck A¹, Yu AP¹, Mallett D², Robinson RL3
	¹Analysis Group, Inc, Boston, MA, USA, ²Ingenix Employer Solutions, New Haven, CT, USA, 3Eli Lilly and Company, Indianapolis, IN, USA

PSY52	INADEQUATE GASTROPROTECTION AMONG NEW CHRONIC USERS OF TRADITIONAL NSAIDS IN THE NETHERLANDS
	Van der Linden MW¹, Kuipers E², Sukel M3, Van den Bemt BJ4, Herings RM5, Gaugris S6
	¹PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands, ²Erasmus University Medical Center, Rotterdam, Netherlands, 3PHARMO Institute, Utrecht, Utrecht, Netherlands, 4St Maartenskliniek, Nijmegen, Gld, Netherlands, 5PHARMO Institute, Utrecht, Netherlands, 6Merck & Co., Inc, Whitehouse Station, NJ, USA

PSY53	HOSPITAL CHARGES AND COMORBIDITIES AMONG OBESE AND MORBIDLY OBESE PATIENTS
	Hlaing WM, Kim SH, Davalos DM
	Florida International University, Miami, FL, USA

PSY54	DEVELOPMENT OF AN OPIOID ROTATION MODEL
	Magar RS¹, Fine PG², White RE3, Victor TW3
	¹PharmIdeas USA, Buffalo, NY, USA, 2University of Utah - Pain Research Center, Salt Lake City, UT, USA, 3Endo Pharmaceuticals, Chadds Ford, PA, USA

PSY55	DIAGNOSIS AND TREATMENT FLOWS FOR MORBIDLY OBESE PATIENTS VISITING PHYSICIAN OFFICES IN THE US
	Pokras S, Klingman D, Tierce J
	IMS Consulting, Falls Church, VA, USA